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Abstract
Guided by the gender-analysis-matrix theoretical framework, 3 key areas of research
inquiries focused on the relationship between sex and Lyme disease, symptoms of Lyme
disease and sex, and severity of Lyme disease symptoms on sex. A quantitative
secondary data analysis was used to address the research questions. A clinician
specializing in caring for individuals with Lyme disease provided the dataset, containing
responses to the Horowitz Multiple Systemic Infectious Disease Syndrome Questionnaire
for Lyme disease. A cross-sectional, comparative research design incorporating 2
statistical techniques for analysis—the independent samples t test and multivariable
regression analyses—was used to examine symptom counts and the severity of symptom,
scoring the severity. Study findings from 235 participants (40 males, 17%, and 195
females, 83%) indicated no sex differences in type, number, and severity of chronic
Lyme disease symptoms. The top 5 Lyme disease symptoms—fatigue, disturbed sleep,
stiff neck or back, neck cracks, and joint pain—ranked the same for males and females,
varying little in percentages. The positive social change implications derived from the
findings of this study are to improve understanding of sex differences in chronic Lyme
disease. This study not only addressed clinical presentations, but also issues of sex bias,
which can result in the development and implementation of sex-based medical,
psychological, and social interventions leading to epidemiological interventions to reduce
the prevalence of this debilitating disease.
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Chapter 1: Introduction to the Study
Introduction
Lyme disease, also known as borreliosis, is an infectious disease that can be
transmitted by the Ixodes tick, if that tick is infected with the Borrelia burgdorferi (B.
burgdorferi) bacterium (Centers for Disease Control and Prevention [CDC], 2015a).
Lyme-literate professionals distinguish between Lyme disease and chronic Lyme disease,
also known as posttreatment Lyme disease (PTLDS; Johns Hopkins Medicine, 2018). In
contrast to Lyme disease, which has specific symptomatology, chronic Lyme disease has
persistent symptoms (Donta, 2012). Most often, the symptoms of chronic Lyme disease
are neurological and cardiac related, neither responding to typical antibiotic treatment nor
to confirmation using serological testing (Lantos, 2015).
Lyme disease appears to affect males and females equally (Rebman, Soloski, &
Aucott, 2015). Lyme disease is far more common in females than males; indeed, chronic
Lyme disease affects nine females for every male (Muñoz-Grajales, González, Alarcón,
& Acosta-Reyes, 2016). The cause of chronic Lyme disease and reasons for the higher
prevalence of chronic Lyme disease among females remain largely unexplained. The goal
of this study was to enhance understanding as to why such sex differences in the
susceptibility, prevalence, and severity of chronic Lyme disease exist.
Severity of symptoms for Lyme disease varies between individuals, whether male
or female. Untreated, undiagnosed, or late diagnosis of Lyme disease leads to serious
health problems that can resemble other indications or conditions, leaving individuals to
experience a variety of symptoms that worsen the longer they are left untreated (Muth,
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2019). The severity of symptoms was scored in this study using a 4-point Likert-type
scale of 0 for none, 1 for mild, 2 for moderate, and 3 for severe for each symptom listed
in the Horowitz Multiple Systemic Infectious Disease Syndrome (MSIDS) Questionnaire
tool, also called the Horowitz MSIDS Questionnaire (HMQ). In this study, I examined
whether significant sex differences exist in reported presentations of Lyme disease, as
well as sex differences in the number and severity of Lyme disease-related symptoms for
males with Lyme disease versus females with Lyme disease.
An increased understanding of potential sex differences regarding chronic Lyme
disease can result in the development and implementation of sex-based medical,
psychological, and social interventions, potentially leading to epidemiological
interventions that reduce the prevalence of this debilitating disease. Sex differences are
important epidemiological factors that impact the prevalence and severity of infectious
diseases (Vázquez-Martínez, García-Gómez, Camacho-Arroyo, & González-Pedrajo,
2018). Sex as a variable in infectious-disease research typically has been overlooked and
the influence of sexual dimorphism (where the two sexes of the same species exhibit
different characteristics beyond the differences in their sexual organs), is probably
underrepresented (Ingersoll, 2017). Sex bias is a major challenge in clinical research, as
major adverse effects observed in single-sex studies cannot forecast whether males and
females will respond differently to a drug, vaccine, or treatment.
Hormonal, genetic and environmental factors between males and females may
influence immune responses and sex-related outcomes, and both sexes should be shielded
against immune-mediated and infectious diseases with the long-term goal of
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individualizing therapies for males and females independently (Ruggieri, Anticoli,
D’Ambrosio, Giordani, & Viora, 2016). Although confounding variables may be of
interest or considered, limitations in the data set used with regard to availability of certain
data elements preclude the incorporation of some potential confounders (e.g., presence of
autoimmune diseases that differ in prevalence between males and females and exhibit
symptoms that are similar to those present in persons with chronic Lyme disease) in this
research analysis.
The purpose of Chapter 1 is to provide a comprehensive overview of this research
study. In the background of the study section, I summarize pertinent empirical literature
and note gaps in this body of literature. These gaps provide the rationale for this study. I
elucidate the statement of the problem and the purpose of the research and present the
research questions and associated null and alternative hypotheses. The chapter continues
with a discussion of the guiding theoretical framework, followed by the nature of the
research, pertinent definitions, research assumptions, an articulation of scope,
delimitations, and limitations. Research outcomes currently available on sex-divergent
responses to treatments and therapies are finite and suggest the need for additional basic
biomedical research in this area, especially with Lyme disease patients (Ruggieri et al.,
2016). A summary section concludes each chapter.
Background of the Study
In 2006, the Infectious Diseases Society of America (IDSA) identified specific
criteria for chronic Lyme disease, identifying Lyme disease as the harbinger of chronic
Lyme disease (Wormser, Dattwyler, Shapiro, Halperin, Steere, Klempner, Krause,
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Bakken, Strle, Stanek, Bockenstedt, Fish, Dumler, Nadelman, 2006). Also, individuals
with chronic Lyme disease must have received a diagnosis of Lyme disease with clinical
findings documented first (Wormers et al., 2006). The IDSA concluded that individuals
with chronic Lyme disease do not respond to oral antibiotics (which is the general course
of treatment for initial Lyme disease), yet report chronic or intermittent symptoms
including extreme fatigue, musculoskeletal pain, neurological and cognitive impairments
persisting at least 6 months after the completion of antibiotic therapy, and other
symptoms so severe that they impede daily functioning (Wormers et al., 2006; Lantos,
2015). This clinical confusion regarding chronic Lyme disease has led to controversial
debates in the literature. Some clinicians and researchers posited that chronic Lyme
disease is a polymicrobial disease distinctly different from Lyme disease and associated
with such diseases as fibromyalgia or chronic fatigue syndrome (Rawls, 2018). Others
defined Lyme disease as a psychosomatic disorder (Lantos, 2015).
Each year, state health departments report more than 300,000 new cases of Lyme
disease to the CDC (2018). This has led the CDC to declare that Lyme disease is the
fastest growing vector-borne infectious disease in the United States (CDC, 2018).
However, factual evidence has shown that between 3 and 28% of individuals initially
diagnosed with Lyme disease progress to chronic Lyme disease (Lantos, 2015). The
dearth of solid data, coupled with the lack of objective clinical tests, compelled
researchers to deduce that the prevalence rate of chronic Lyme disease in the general
population has “become nearly impossible to discern” (Lantos, 2015, p. 326).
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Empirical evidence demonstrated similar prevalence rates of Lyme disease across
sex groups; yet in contrast, individuals with chronic Lyme disease are considerably more
likely to be females than males, with prevalence ratios ranging from 7:1 to 9:1 (Wormser
& Shapiro, 2009). Researchers have conducted several analyses to better understand sexbased differences in the epidemiology, clinical presentation, and immunologic response
of chronic Lyme disease. Case in point, Rebman et al. (2015) observed sex differences in
immune responses to Lyme disease that may promote the observation of higher rates of
Lyme disease among females. Basic immune responses diverge between females and
males, and it is evident that females have higher absolute numbers of CD4+ lymphocytes
compared to males, which may contribute to their increased immune responses
(Whitacre, 2001). The Whitacre and Rebman studies did not consider differences in
Lyme disease symptomatology based on sex. Although sex hormones have long been
recognized for their roles in reproductive functions, in the past 2 decades, scientists have
observed that sex hormones are fundamental signaling modulators of the mammalian
immune system (Ackerman, 2006). Additionally, sex hormones have conclusive roles in
lymphocyte maturation, activation, and the synthesis of antibodies and cytokines, as these
hormones contribute to the creation of autoimmunity (Ackerman, 2006).
Lyme disease impacts people in different ways and diagnosing the chronic form
of the disease is challenging (Lymedisease.org, 2015). Lyme disease takes, on average, 2
years for an individual to obtain a correct diagnosis (Auwaerter, 2015; LymeDisease.org,
2015). The prevalence of Lyme disease among females may be higher than is reported,
resulting from misdiagnoses (Wormer & Shapiro, 2009). Females who had been
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diagnosed or misdiagnosed with such illnesses as fibromyalgia, chronic fatigue
syndrome, or depression may actually have chronic Lyme disease (Wormser & Shapiro,
2009). Imperfect diagnostic tools for Lyme disease may also contribute to its underidentification and subsequent misdiagnoses, mostly for females (Aucott, Morrison,
Munoz, Rowe, & Schwarzwalder, 2009). In response to the potential for misdiagnosis,
Horowitz (2013) developed the Horowitz differential diagnostic approach as a road map
to identify the multiple elements of the MSIDS questionnaire tool. The MSIDS
questionnaire has been validated as a tool for distinguishing between individuals with
confirmed Lyme disease and healthy individuals without Lyme disease (Citera, Freeman,
& Horowitz, 2017) in the clinical-assessment stage. The HMQ has been deemed valid
and effective as a low-cost screening tool for medical practitioners to assist in the
necessary clinical assessment of individuals presenting with possible Lyme disease or
related tick-borne infections (Citera et al., 2017).
In a small retrospective study with 125 participants, Schwarzwalder, Schneider,
Lydecker, and Aucott (2010) found verification of sex-based differences using the
Enzyme-Linked Immunosorbent Assay (ELISA) and Immunoglobulin G (IgG) serologic
response to early Lyme-disease stages. Schwarzwalder et al. acknowledged that such
differences could have cognizant implications on the merit of diagnosis, treatment, and
disease classification. A later study further underscored a sex-based gap (Rebman et al.,
2015). Although some research has been done in this area, referencing a research study
with a sample size of 85 individuals (Ljøstad & Mygland, 2009), additional research is
needed to appreciate the extent of the differences between the sexes and Lyme disease,
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from the earliest stages of antigen exposure to the final effector stages of immunity in
response to exogenous and self-antigens (Whitacre, 2001).
The identification of individuals with Lyme disease is a major health concern and
a critical public health threat in the United States and Europe (Citera et al., 2017). This
problem is on the brink of becoming the most prevalent spreading vector-borne epidemic
worldwide, as pathogen-carrying ticks ride migratory birds throughout wide geographic
areas, proliferating the infection (Citera et al., 2017). Much remains unexplored and
undiscovered regarding sex and sex-based differences in the epidemiology, clinical
presentation, and immunologic response to chronic Lyme disease (Rebman et al., 2015).
Additionally, treatment and therapies are not sex specific of gender-sensitive medicine,
and specific data on sex differences are lacking (Guerra-Silveira & Abad-Franch, 2013).
Problem Statement
Lyme disease is suspected to be a parasitic infection transmitted by the bite of a
hard tick associated with several species of the genus Ixodes (Hatchette et al., 2015).
Lyme-literate practitioners hypothesize that a parasitic association with Lyme-disease
infection is evident due to the discovery of multiple microbes contributing to this illness
and indication. The ongoing battle in this research is due to multiple strains of Borrelia
and coinfections on top of Lyme infection relates primarily to different types of ticks in
many geographic locations (Rawls, 2018). Different strains of Borrelia species have been
confirmed as causative agents of Lyme disease with 100 known strains in the United
States and 300 strains worldwide (Lymestats.org, 2018). Because Lyme disease impacts
people differently, and depending on susceptibility criteria such as sex, the symptoms of
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Lyme disease may not appear for many years (Columbia University Irvine Medical
Center, 2018). Thus, a correct diagnosis is quite difficult. Lyme disease is often
misdiagnosed as many other indications including psoriatic arthritis, joint pain, multiple
sclerosis, rheumatoid arthritis, chronic fatigue syndrome, thyroid disease, amyotrophic
lateral sclerosis, and the four types of lupus: systemic lupus erythematosus, discoid
(cutaneous), drug-induced lupus, and neonatal lupus (CanLyme, n.d.). As symptoms
manifest uniquely for each individual through several factors and variables, no
standardized diagnostic test exists, though one test generally used to diagnose early Lyme
disease is the western-blotting method (Mayo Clinic Staff, 2018).
Western blotting is a method and sensitive assay used for immunodetection and
characterization of specific proteins by taking advantage of the specificity inherent in
antigen–antibody recognition (Gallagher & Chakavarti, 2008). Tests, such as the western
blot test, identify antibodies to the Borrelia bacteria strain and not the bacteria itself
(IGeneX, 2017). These antibodies may not have been produced by the body in a quantity
necessary to show a positive outcome in diagnostic results. Specificity to a diagnostic test
will indicate the level of the specific antigen or antibodies found in the sample and
provides a level of confidence that the individual has the disease, even if dormant at the
time of drawing the blood sample negative (Lalkhen & McCluskey, 2008). The
sensitivity of a diagnostic test can correctly identify those individuals with the disease, so
if the highly sensitive test is negative, the individual does not have the disease, called a
true negative (Lalkhen & McCluskey, 2008).
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The western-blot test for Lyme disease provides a second-tier confirmation of the
physician assessment of clinical symptoms (CDC, 2015b). Most treating physicians do
not elucidate patients’ familial history of Lyme disease or biological sex as factors for
Lyme disease (vom Steeg & Klein, 2016). Individuals with chronic Lyme disease are
significantly more likely to be females than individuals diagnosed with either Lyme
disease or post-Lyme disease syndrome (Wormser & Shapiro, 2009). Based on this
finding, individuals with chronic Lyme disease consistently diverge as a function of sex
from individuals with B. burgdorferi infection or post-Lyme-disease syndrome. Also,
illnesses such as fibromyalgia, chronic fatigue syndrome, or depression, with a female
preponderance, could be misdiagnosed as chronic Lyme disease (Wormser & Shapiro,
2009).
In another study, the biological plausibility of sex effects on Lyme disease was
explored with a review of charts or medical records. In 2010, researchers demonstrated
no remarkable differences in clinical presentation of Lyme disease by sex
(Schwarzwalder et al., 2010). However, a positive ELISA and median number of IgG
bands were significantly higher among males. Sex-based differences in the magnitude of
ELISA and IgG serologic response to early Lyme disease occurred (Schwarzwalder et al.,
2010). As a result, such differences have consequences for the relevance of diagnosis,
treatment, and perhaps disease classification (Schwarzwalder et al., 2010).
Overall, more studies are needed to evaluate a sex-based link to Lyme disease
(Schwarzwalder et al., 2010). Sex is important in health, health care, and medical
research, due to practitioners knowing predisposition such as females being more likely
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to suffer from autoimmune diseases, have osteoporosis, depression, and anxiety, whereas
males are more likely to develop Parkinson’s disease and cardiovascular disease early in
life, according to researchers at Stanford University (Conger, 2017). Also, researchers at
Stanford University are finding increasing evidence of the influence of biological sex on
health pertaining to disease, indicating researchers are just beginning to understand the
magnitude of the problem (Conger, 2017).
Lyme disease has generated a great deal of controversy over a long period of time
(Pettengill, 2018). Currently, diagnosis of Lyme disease is a clinical diagnosis or
assessment, primarily determined by evaluating an individual’s medical history,
symptoms, and exposure to ticks (Lymedisease.org, 2018b). Most physicians and
practitioners, excluding those who are Lyme-literate, follow the CDC recommended
testing strategy, which is a two-step testing algorithm, screening with an ELISA test, and
reflecting positive or equivocal results in western-blot tests (Pettengill, 2018). Lyme
disease hinders an individual’s immune system, so it does not react or respond to the
infection. Thus, 20 to 30% of tests create false-negative antibody results
(Lymedisease.org, 2018b).
As previously explained, if a diagnostic test for Lyme disease is sufficiently
specific, the specificity to a diagnostic test will indicate the level of the specific antigen
or antibodies found in the blood sample, thereby providing a level of confidence that the
individual has the disease, even if dormant at the time of drawing the blood sample
(Lalkhen & McCluskey, 2008). When the specificity is low, false negatives occur
(Gallagher & Chakavarti, 2008). When the Borrelia burgdorferi bacterium is transmitted
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to an individual, it quickly evades recognition and attack from the individual’s immune
system by first changing proteins on its outer cell wall, thereby effectively disguising
itself and hiding in the tissues before eventually forming a slimy substance called a
biofilm (Holtorf Medical Group, 2019). The biofilm becomes a very protective layer that
renders the bacteria up to 1,000 times more resistant to antibiotics than other bacteria
(Sapi et al., 2016).
Sex analysis is a critical element of health systems research (London School of
Hygiene & Tropical Medicine, 2014). For this study, it was essential to distinguish
between sex and gender. Most societies view biological sex as a binary concept, with two
firmly fixed categories (male and female), based on a person’s reproductive functions,
(e.g., genitals, sex chromosomes, gonads, hormones, reproductive structures; Gender
Spectrum, 2017). Sex refers to male and female, as gender refers to masculine and
feminine (Nobelius, 2004). In general terms, sex refers to the biological differences
between males and females, such as the genitalia and genetic differences, whereas gender
is more difficult to define but can refer to the role of a man or woman in society, or an
individual’s concept of themselves (i.e., gender identity; Newman, 2016). Male and
female genitalia, internal and external, are different; similarly, levels and types of
hormones present in male and female bodies are different (Newman, 2016). These vital
divergent factors must be considered in treating Lyme disease and associated
autoimmune disease (Horowitz, 2013). As an example, females with rheumatoid arthritis
experience a significant delay in referrals to an early arthritis clinic in comparison with
males (Regitz-Zagrosek, 2012).
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Sex analysis can be incorporated into health-systems research at any stage of the
research process and includes the consideration of sex when defining the research aim,
objectives, or questions in the development of the study design and data-collection tools,
the process of data collection, the explication and exchange of results, and in researchuptake activities (London School of Hygiene & Tropical Medicine, 2014). Sex
frameworks and tools can help researchers create research methods, inclusive of research
questions, data collection, and analysis (London School of Hygiene & Tropical Medicine,
2014).
Several studies addressed human male–female differences in overall mortality,
susceptibility to allergic and autoimmune diseases, or individual infectious disease risk;
yet surprisingly, a comprehensive test of the major hypotheses outlined above is currently
unavailable (Guerra-Silveira & Abad-Franch, 2013), to the best of my knowledge. The
use of sex analysis is now affording beneficial new insights into prevention and
management of chronic diseases such as Lyme disease in all stages of infection
(Canadian Women’s Health Network [CWHN], 2012).
Despite growing appreciation of the gravity of sex-driven elements, progress
toward sex assimilation as standard practice has been gradual and inconsistent in health
research and medical practice (Day, Mason, Logusky, & Rochon, 2016). It is often
assumed that males and females have the same symptoms for infectious diseases.
Biological differences between males and females should be acknowledged and
contemplated in emerging disease programs (World Health Organization [WHO], 2011).
Approximately 79% of people worldwide (as of 2012), diagnosed with an autoimmune
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disease, are females (CWHN, 2012). These diseases also often occur divergently in males
and females, with various ages of onset and an assortment of symptoms (CWHN, 2012).
Purpose of the Study
This study was designed to investigate the epidemiologic consequence of sexbased differences of chronic Lyme disease. Sex differences in the pathogenesis of
infectious diseases may reflect variations with immune responses during infection (vom
Steeg & Klein, 2016). The lack of expertise about the relationship of sex to infectious
diseases has been shown in a variety of disciplines including epidemiology, medical and
biological sciences, social sciences, and demography (WHO, 2007). If infectious diseases
are considered in the context of biological sex, it could be hypothesized that sex results in
physiological differences (e.g., hormonal regulation of immune responses) in the control
and clearance of a pathogen, as well as in anatomical differences that may influence
exposure and transmission of a pathogen (vom Steeg & Klein, 2016). Important sex
differences in the brain seem to arise from biology; an example is gonadal sex steroids or
genes found on sex chromosomes that influence sex differences in neuroanatomy,
neurochemistry and neuronal structure, and connectivity (Zagni, Simoni, & Colombo,
2016). The sexes differ in the intensity, prevalence, and pathogenesis of infections caused
by viruses, bacteria, parasites, and fungi (vom Steeg & Klein, 2016).
This study entailed a comparative social inquiry to determine if a statistically
significant difference between the sexes would emerge in chronic Lyme symptomatology
and severity, which has not been defined in the outcome analyses of Lyme disease by
sex. Sex significantly contributes to shape immune responses, contributing to variation in
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the pathogenesis of infectious disease in males and females, and the prevalence of what is
called autoimmune diseases (Ruggieri et al, 2016). Males and females differ in their
innate immune responses, which is one part of the immune system that responds when
activated by the presence of antigens and their chemical properties, suggesting that some
sex differences are germ line-encoded (vom Steeg & Klein, 2016). The sexes provide
various genetic backgrounds, anatomic niches, immunological profiles, and hormonal
situations that can be directly affected by pathogens such as viruses, bacteria, parasites,
and fungi, as well as the chronic development of diseases following infection (vom Steeg
& Klein, 2016). Hormones, genes, and behaviors contribute greatly to sex differences in
the culmination of infection (vom Steeg & Klein, 2016). Lyme disease is considered a
polymicrobial infection, thereby inferring that Lyme disease is not a single or stand-alone
infection (Rawls, 2018). Key variables investigated for a comparative assessment were
biological sex (male or female) and chronic Lyme condition symptomatology.
The evidence is fast becoming clear that chronic disease affects males and
females differently, but this is relatively new knowledge. Until now, most research on
chronic disease did not consider biological sex (CWHN, 2012). The U.S. National
Institute of Mental Health has recommended the incorporation of sex as a variable in
experimental and clinical studies to address sexual dimorphisms influencing sex
differences when treating chronic disease indications, such as Lyme disease (Zagni et al.,
2016). In most cases, the exact mechanism interposing the dimorphism in infectious
disease pathogenesis is unknown, partly because sex has not been considered a biological
variable for the analysis of outcome data (vom Steeg & Klein, 2016).
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Increasing evidence confirms that sexual dimorphism in bacterial infections has
been mainly attributed to the differential levels of sex hormones between males and
females and sex-bias also depends on the effects of sex hormones on specific bacterial
species (Vázquez-Martínez et al., 2018). Additionally, sex differences are important
epidemiological factors that affect the severity of infectious diseases, with current
research showing males as more susceptible to gastrointestinal and respiratory bacterial
diseases and sepsis, and females more susceptible to genitourinary tract bacterial
infections, highlighting the role of specific hormone receptors involved in the sex-bias of
bacterial infections (Vázquez-Martínez et al., 2018). In this study, I examined if critical
symptoms and severity are delineated by sex; these factors were not defined specifically
in previous outcome analyses of Lyme disease subjects by sex.
Research Questions
The study focused on investigating the research gap, based on biological sex and
Lyme disease, by exploring the following research questions:
RQ1: What is the relationship between biological sex and the frequency of
symptoms (unexplained fevers, sweats, chills, or flushing; unexplained weight change
[loss or gain]; fatigue, tiredness; unexplained hair loss, swollen glands; sore throat;
testicular pain/pelvic pain; unexplained menstrual irregularity; unexplained breast milk
production, breast pain; irritable bladder or bladder dysfunction; sexual dysfunction/loss
of libido; upset stomach; change in bowel function [constipation or diarrhea]; chest pain
or rib soreness; shortness of breath/cough; heart palpitations, pulse skips, heart block;
history of heart murmur or valve prolapse; joint pain or swelling; stiffness of the neck or
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back; muscle pain or cramps; twitching of the face or other muscles; headaches; neck
cracks or neck stiffness; tingling, numbness, burning or stabbing sensations; facial
paralysis [Bell’s Palsy]; eyes/vision—double, blurry; ears/hearing—buzzing, ringing, ear
pain; increased motion sickness, vertigo; lightheadedness, poor balance, difficulty
walking; tremors; confusion, difficulty thinking; difficulty with concentration or reading;
forgetfulness, poor short term memory; disorientation; getting lost, going to wrong
places; difficulty with speech or writing; mood swings, irritability, depression; disturbed
sleep—too much, too little, early awake; exaggerated symptoms or worse hangover from
alcohol, (Citera et al., 2017) of individuals with confirmed chronic Lyme disease?
H01: No statistically significant relationship exists between biological sex and the
symptoms of individuals with confirmed chronic Lyme disease.
Ha1: A statistically significant relationship exists between biological sex and the
symptoms of individuals with confirmed chronic Lyme disease.
RQ2: Are there differences in the number of symptoms (unexplained fevers,
sweats, chills, or flushing; unexplained weight change [loss or gain]; fatigue, tiredness;
unexplained hair loss, swollen glands; sore throat; testicular pain/pelvic pain;
unexplained menstrual irregularity; unexplained breast milk production, breast pain;
irritable bladder or bladder dysfunction; sexual dysfunction/loss of libido; upset stomach;
change in bowel function [constipation or diarrhea]; chest pain or rib soreness; shortness
of breath/cough; heart palpitations, pulse skips, heart block; history of heart murmur or
valve prolapse; joint pain or swelling; stiffness of the neck or back; muscle pain or
cramps; twitching of the face or other muscles; headaches; neck cracks or neck stiffness;
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tingling, numbness, burning or stabbing sensations; facial paralysis [Bell’s Palsy];
eyes/vision—double, blurry; ears/hearing—buzzing, ringing, ear pain; increased motion
sickness, vertigo; lightheadedness, poor balance, difficulty walking; tremors; confusion,
difficulty thinking; difficulty with concentration or reading; forgetfulness, poor short
term memory; disorientation; getting lost, going to wrong places; difficulty with speech
or writing; mood swings, irritability, depression; disturbed sleep—too much, too little,
early awake; exaggerated symptoms or worse hangover from alcohol; Citera et al., 2017)
associated with Lyme disease between adult females compared with adult males
diagnosed with Lyme disease?
H02: No statistically significant differences exist in the number of symptoms
associated with chronic Lyme disease between adult females and adult males
diagnosed with chronic Lyme disease.
Ha2: Statistically significant differences exist in the number of symptoms
associated with chronic Lyme disease between adult females and adult males
diagnosed with chronic Lyme disease.
RQ3: Are there significant differences in the severity of symptoms associated
with chronic Lyme disease between adult females and adult males diagnosed with
chronic Lyme disease?
H03: No statistically significant differences exist in the severity of symptoms
associated with chronic Lyme disease between adult females and adult males
diagnosed with chronic Lyme disease.
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Ha3: Statistically significant differences exist in the severity of symptoms
associated with chronic Lyme disease between adult females and adult males
diagnosed with chronic Lyme disease.
Theoretical Foundation
The WHO gender-analysis-matrix (GAM) for emerging infectious diseases
provided a meaningful theoretical framework for this study. I selected the GAM as the
theoretical foundation because the model contains relevant constructs on infectious
disease and on the exploration of effects of sex on disease transmissions and outcomes
(WHO, 2011). The WHO GAM is an analytical tool that uses a participatory
methodology to simplify the definition and analysis of sex issues by communities that are
affected by them, and specifically in connection to chronic Lyme disease compared to
chronic illnesses (Global Development Research Center, 2016). The participatory
methodology of the GAM matrix was described using a simple 38 x 2 table format,
modified to include the 38 symptoms on the x-axis and males and females on the y-axis.
The participatory method includes the males and females of the community (sample) in
two groups to estimate the associated symptoms per group. The GAM matrix comprised
an x-axis that represents Levels of Analysis (symptoms) and a y-axis for the Categories
of Analysis (sex—male/female) confirmed chronic Lyme disease (Global Development
Research Center, 2016).
An example of the table and modified matrix appear in Table 1.
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Table 1
List of Symptoms Derived From HMQ
List of symptoms

Males

Females

Unexplained fevers, sweats, chills, or flushing
Unexplained weight change (Loss or Gain)
Fatigue, tiredness
Unexplained hair loss
Swollen glands
Sore throat
Testicular pain/Pelvic Pain
Unexplained menstrual irregularity
Unexplained breast milk production, breast pain
Irritable bladder or bladder dysfunction
Sexual dysfunction / loss of libido
Upset stomach
Change in bowel function (Constipation or Diarrhea)
Chest pain or Rib soreness
Shortness of Breath / Cough
Heart palpitations, pulse skips, heart block
History of Heart Murmur or Valve Prolapse
Joint pain or Swelling
Stiffness of the neck or back
Muscle pain or cramps
Twitching of the face or other muscles
Headaches
Neck cracks or Neck Stiffness
Tingling, numbness, burning or stabbing sensations
Facial Paralysis (Bell’s Palsy)
Eyes/Vision – Double, Blurry
Ears/Hearing – Buzzing, Ringing, Ear Pain
Increased motion sickness, vertigo

(table continues)
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List of symptoms

Males

Females

Lightheadedness, poor balance, difficulty walking
Tremors
Confusion, difficulty thinking
Difficulty with concentration or reading
Forgetfulness, poor short-term memory
Disorientation; getting lost, going to wrong places
Difficulty with speech or writing
Mood swings, irritability, depression
Disturbed sleep—Too Much, Too Little, Early Awake
Exaggerated symptoms or worse hangover from alcohol
Source: “Empirical Validation of the Horowitz Multiple Systemic Infectious Disease Syndrome
Questionnaire for Suspected Lyme Disease, by M. Citera, P. Freeman, & R. Horowitz, 2017, International
Journal of General Medicine, 2017(10), 249–273.

Conceptual Framework
The conceptual framework builds on aspects that influence health outcomes using
health-related considerations such as sex-specific treatments and therapies, given that
incidence of infectious disease is often male biased (Guerra-Silveira & Abad-Franch,
2013). Researchers proposed two main hypotheses to explain this observation: the
physiological hypothesis emphasizes differences in sex hormones and genetic
architecture, and the behavioral hypothesis stresses sex-related differences in exposure
(Guerra-Silveira & Abad-Franch, 2013).
Gender medicine must consider the needs of both sexes. For instance, more data
on males are necessary on osteoporosis and depression, while more data on females are
urgently called for in the cardiovascular area (Regitz-Zagrosek, 2012) and for infectious
diseases. The new conceptualization of evidence-based sex-based medicine, which
includes primary variations of biology and behavior between males and females, should
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enhance health care for both sexes (Regitz-Zagrosek, 2012). Aggregated data sets can
mask differences between the sexes, leading to assumptions that all individuals share the
same experiences; this bias can impact the validity and reliability of research in nullifying
ways (London School of Hygiene & Tropical Medicine, 2014).
Biological sex influences a wide range of physiological functions and influences a
wide assortment of diseases including those of the cardiovascular, pulmonary, and
autoimmune systems, as well as diseases encompassing gastroenterology, hepatology,
nephrology, endocrinology, hematology, and neurology (Oertelt-Prigione & RegitzZagrosek, 2012). The scientific literature reflects sex distinctions with over 10,000
articles addressing sex differences in clinical medicine, epidemiology, pathophysiology,
clinical manifestations, outcomes, and management (Regitz-Zagrosek, 2012). A new
curiosity in understanding the biology of this disparity, as well as funding opportunities,
has directed attention to research priorities on sex differences (Whitacre, 2001).
Nature of the Study
This study employed a cross-sectional comparative-research design with a
quantitative method. Secondary data were used in the study analysis. Information
obtained from psychometrically validated surveys was used to examine the sex of
patients to see if sex links to the severity of Lyme disease and symptoms (Citera et al.,
2017). The sex of individuals with Lyme disease was the independent variable and the
number of symptoms and severity of symptoms were the dependent variables in this
study. Information on participants’ sex, the primary independent variable of the study,
was assessed while accounting any covariates and confounders that may have influenced
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the severity of the outcome under investigation. The data collection and participant
selection were from a sample of adults in the target population in the United States.
Patients were positively diagnosed with chronic Lyme disease.
The quantitative-method design used in this study was best described as a crosssectional comparative research design. A cross-sectional comparative quantitative-survey
research design was used to compare females to males on several parameters.
Participants’ survey information was obtained from the HMQ for Lyme disease.
Horowitz provided a data set for this study, and those data were used for the analyses.
Definitions
The terms and concepts listed below were defined in the framework of an
epidemiologic study.
Autoimmune disease: The term autoimmune disease refers to a varied group of
illnesses that involve almost every human organ system such as diseases of the nervous,
gastrointestinal, and endocrine systems, as well as skin and other connective tissues, eyes,
blood and blood vessels (American Academy of Allergy, Asthma, & Immunology, 2018).
Autoimmunity: Autoimmunity is the underlying problem in autoimmune diseases
because the body’s immune system becomes misdirected and attacks the organs it was
designed to protect (American Autoimmune Related Diseases Association, 2017).
Borrelia burgdorferi: Borrelia burgdorferi (B. burgdorferi) is a spirochete tickborne obligate parasite whose normal reservoir is a variety of small mammals in the
United States (Burgdorfer et al., 1982). Whereas infection of these natural hosts does not
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lead to disease, infection of humans can result in Lyme disease, as a consequence of the
human immunopathological response to B. burgdorferi (Wooten & Weis, 2001).
Gender: Gender refers to the role of a man or woman in society (gender role), or
an individual’s concept of themselves (gender identity; Newman, 2016).
Lyme disease: Lyme disease is a multisystem disorder that may involve
dermatological, musculoskeletal, nervous system, or cardiac manifestations (Artsob,
1993).
Sex: Sex refers to male and female, as gender refers to masculine and feminine
(Nobelius, 2004).
Assumptions
This research was based on assumptions. With regard to data collection and
analysis in this study, the first assumption was that all participants consented to complete
the questionnaire as part of the validation study from which the secondary data set was
derived. Horowitz granted access to a data set from the validation study published in
December 2017.
The second assumption was that the sample population in the data set of 236
participants was sufficient for the analysis of this research. The sample size was
determined to be acceptable to establish at least an 80% statistical power. As the data set
was known to include 236 subjects, the power was determined based on the data set
provided by Horowitz.
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Scope and Delimitations
The delimitations defining the boundaries of this research were based on the data
set authorized for use by Horowitz from the 2017 validation study for the HMQ. The data
set provided did not provide personal demographics of participants such as residence,
date of first infection, date of diagnosis, or any treatment received for Lyme disease. For
this research, I used the data set to compare the specific sample of participant data
between males and females and the symptoms and severity identified through the
anonymous completion of the questionnaire.
Limitations
The limitations for the design and methodology for this research were influenced
by the data set provided by Horowitz’s (2017) validation study. The first limitation for
this cross-sectional study design related to sample bias. The data set provided for this
research consisted of a subsample of a larger sample of individuals with confirmed Lyme
disease, recruited from three medical practices involved in the data-collection study. The
data accrued through recruitment in social media and the questionnaire survey was
provided by e-mail invitation, directing potential participants to click on a link explaining
the purpose of the survey and informed-consent information (Citera et al., 2017). The
cross-sectional study design reflected bias, identifying prevalent cases rather than
incident cases.
The second limitation to the study was recall bias. Cross-sectional studies may
also exhibit recall bias, because disease or assessment of disease may influence
participants’ responses to questionnaires (Thelle & Laake, 2015). The study may be
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limited on practical importance because the purpose of this study was not tailored to the
practical aspects of Lyme-disease intervention. That is, no treatments or interventions
were included in the data collection. All survey responses were anonymous with no
identifying information requested from participants; the time, location, or known
transmission of the infection were not included in the data set used for this research
(Citera et al., 2017). For a quantitative method, its application was not used to or
effectively measure subjective experiences or emotional states of individuals affected by
an outcome or those who are exposed to a risk factor (DiClemente, Salazar, & Crosby,
2013; Frankfort-Nachmias & Nachmias, 2008).
Significance
The relevance of this current study as it relates to the intent to address the
identified gap was that the impact of sex-based differences on chronic Lyme-disease
infections abridge the substantial lapses in misdiagnosis and treatment of the disease.
Despite nearly 4 decades of scientific inquiry into transmission dynamics,
immunopathology, and treatment outcomes of Lyme disease, much remains unknown,
with a general lack of research examining potential sex-based differences in this
infectious-disease setting (Klein & Roberts, 2015). The abridged gap would promote
effective health measures on practical intervention approaches for chronic Lyme disease.
Hence, understanding differences between sex influences on the issues of the
pathophysiology of Lyme neuroborreliosis, PTLDS or chronic Lyme disease, may allow
for better knowledge of underlying differences in the immune response between males
and females following infection, which could affect pathogen clearance, development of
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autoimmune-like responses, and seroconversion on two-tier antibody tests (Rebman et
al., 2015). The sex differences in autoimmune diseases underscore the necessity for sex
analysis (CWHN, 2012). These diseases also often occur differently in males and
females, with different ages of onset and different kinds of symptoms (CWHN, 2012).
The improvement of medical, public health, epidemiological, and social practices
on sex-driven approaches to addressing chronic Lyme disease may substantially reduce
the incidence and prevalence of Lyme disease in a target population. Such unique
contributions would advance research, health-promotion measures, advocacy awareness,
and informed decision-making processes in individual, organizational, and social settings.
Current research has the potential to inform future research of new initiatives for a
therapeutic approach that can alter disease pathogenesis, rather than targeting disease
sequelae (Ackerman, 2006). Therefore, the positive social-change implications derived
from the findings of this study could substantially improve understanding of
epidemiologic sex-based factors and considerations for diagnosis, testing, and choice of
treatment options on personal, sex-specific, and social well-being.
If any correlation exists based on sex-based link to the number of symptoms and
the severity of symptoms, then positive social-change implications would not be limited
only to advancement of current testing approaches, but potentially could encourage better
Lyme-disease education and understanding, awareness, and choice of health care
treatment options. In practice, any connection between sex to the number and severity of
symptoms could allow practitioners or epidemiologists the opportunity to effectively
measure the incidence, prevalence, risk of Lyme disease, and subsequent parameters
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based on sex-specific criteria or assays. An example of subsequent parameters is the
clinical-practice guidelines that insurance companies follow for coverage of the treatment
for Lyme disease. These parameters must be met and followed by general practitioners
for insurance coverage to be used for treatment of this disease. That is, the type of
antibiotic treatment and therapies and duration of these treatments are parameters
outlined by insurance companies, respectively. The theoretical application of the GAM in
this study supports population-based benefits and perceptions of sex-driven differences,
not as a weakness of individual integrity, but as a strength in medical practices, public
health programs, epidemiological studies, and social consciousness of the population.
Summary
In summary, hormones, genes, and behaviors contribute significantly to biological
sex differences in the outcome of infection (Klein & Roberts, 2015). Lyme disease
affects males and females differently, as does the different age of onset, and different
kinds of symptoms (CWHN, 2012). Researchers at the Lyme Disease Research
Foundation in Lutherville, MD, evidenced preliminary findings indicating females with
Lyme disease display more clinical symptoms than do males with Lyme disease and are
also less likely to seroconvert on antibody tests for serodiagnosis of Lyme disease
following treatment (Worcester, 2012).
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Chapter 2: Literature Review
Introduction
The incidence of Lyme disease increased from over 3.5 cases per 100,000 people
in 1991 to 8.1 cases per 100,000 in 2016 in the United States (CDC, 2017). Lyme disease
affects individuals differently, and it can take almost 2 years to have an accurate
diagnosis of Lyme disease, due to the variability of the symptoms or lack thereof
(Auwaerter, 2015; Lymedisease.org, 2015). Individuals diagnosed with Lyme disease,
chronic Lyme disease, or post-Lyme disease syndrome are more likely to be females than
males (Wormser & Shapiro, 2009). Yet, uncertainties persist concerning the influence of
sex on symptoms, severity of symptoms, and health-related quality of life between males
and females diagnosed with Lyme disease. These uncertainties suggest the need for
further epidemiological studies to explore this gap in the literature. Rebman et al. (2015)
emphasized that sex-based uncertainties still exist in the exploration of Lyme disease
severity and symptomatology. These authors noted that sex-based differences of the
host’s immune system for Lyme disease response should be explored at the cellular level
as well as after early and late manifestations of Lyme disease (Rebman et al., 2015).
These researchers concluded that sex-based differences in the epidemiology, clinical
presentation, and immunologic response of Lyme disease infections remain unspecified
at this time (Rebman et al., 2015), thereby leaving a gap in the literature on this topic.
This chapter provides a review of literature describing the justification for further
Lyme disease research inquiry, based on prior publications on this topic. I describe and
summarize the conclusions of several published studies relating to the topic under
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investigation and the relevance of these studies to the problem statement and purpose of
this study.
Literature Search Strategy
The literature reviews for this research topic were accessed through various
databases including ProQuest, Google, Google Scholar, PubMed, Medscape, Journal
Watch, and Clinicaltrials.gov. The literature review for this study included peer-reviewed
journals and non-peer-reviewed articles. Nonfiction books and publications written by
Lyme-literate medical practitioners, patients, and private Lyme organizations were also
reviewed. Considering that sex and gender are often mistakenly used as interchangeable
terms, distinct searches were performed using the terms sex and gender with Lyme
disease, and infectious diseases. The search terms used for online publications included
Lyme disease, Lyme disease diagnosis and treatment, Lyme disease and family history,
Lyme disease and sex/gender disparities, susceptibility to Lyme disease, Lyme
Encephalopathy, Lyme disease and health-related quality of life, Lyme disease and
sex/gender differences, Lyme disease and IGeneX testing, Western Blot testing for Lyme
disease, state reporting guidelines for Lyme disease cases, sex and gender differences in
health, sex gap and autoimmune diseases, sex and gender differences with infectious
diseases, and sex and autoimmune diseases.
As a paradigm of this search pattern, I performed the literature search using
PubMed for Lyme-disease conditions with the key term Lyme disease. Keywords
generated a total of 42 articles published from 1984 to 2017. Searches performed with the
keywords sex/gender differences of Lyme disease generated only one article in the
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American Journal of Epidemiology database. Similarly, I searched using the term sex
differences of Lyme disease, and from this search three articles emerged. In contrast, a
literature search in the American Journal of Epidemiology using the term gender
differences of Lyme disease generated two articles. Comparable literature searches were
performed using the databases specified above.
Theoretical Foundation
The WHO’s GAM (2011) for emerging infectious diseases was used as the
theoretical framework for this study. I selected the GAM as the framing foundation
because the model contains relevant constructs on infectious disease and on the
exploration of the effects of sex and gender on disease transmissions and outcomes
(WHO, 2011). I considered the WHO GAM as the foundation for sex and gender,
engaged as a tool used to analyze the impact of male–female differences on emerging
infectious diseases (WHO, 2011).
Another interesting use of the GAM was the WHO Gender Mainstreaming
Manual for Health Managers which also addresses issues with malaria, such as in the
United Republic of Tanzania where some evidence indicates that malaria treatment
practices differ by the sex of the clinician (WHO, 2011). Aside from pregnancy, possibly
complicating the course of malaria with risks for females and children, regardless of the
child’s sex, the use of the GAM framework uncovered the possibility that when one or
several family members contracted malaria, females become overburdened by the
responsibility of caring for sick people (WHO, 2011).
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Sex analysis is an important component of health-systems research (London
School of Hygiene & Tropical Medicine, 2014). For this study, it was important to
distinguish between sex and gender. Most societies view sex as a binary concept, with
two rigidly fixed categories (male and female) based on an individual’s reproductive
functions, (i.e., genitals, gender chromosomes, gonads, hormones, reproductive
structures; Gender Spectrum, 2017; Newman, 2016). Sex refers to male or female, but
gender refers to masculine or feminine (Nobelius, 2004). In general terms, sex refers to
the biological differences between males and females, but gender is more difficult to
define. Gender can refer to the role of a man or woman in society (i.e., gender role), or it
can refer to individuals’ concepts of themselves (i.e., a gender identity; Newman, 2016).
Male and female genitalia, internal and external, are different; similarly, the levels
and types of hormones present in male and female bodies are also different (Newman,
2016). These factors must be considered when treating for Lyme disease and associated
autoimmune diseases (Horowitz, 2013). As an illustration, the referral of female
individuals with rheumatoid arthritis to an early arthritis clinic was considerably delayed
in comparison with male individuals (Regitz-Zagrosek, 2012).
Sex analysis can be incorporated into health-systems research at any stage of the
research process. Consideration of biological sex differences must be made when
defining the research aim, objectives, or questions during the development of the study
design and data-collection tools, the process of data collection, the interpretation and
communication of results, and the research-uptake activities (London School of Hygiene
& Tropical Medicine, 2014). Sex frameworks and tools can help researchers develop
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their research methods, including research questions, data collection, and analysis
(London School of Hygiene & Tropical Medicine, 2014). Several studies addressed
human male–female differences in overall mortality, susceptibility to allergic and
autoimmune diseases, or individual infectious-disease risk. Yet, a critical and
comprehensive test of the major hypotheses outlined above is currently unavailable
(Guerra-Silveira & Abad-Franch, 2013).
Conceptual Framework
Conceptual frameworks are particularly common when research involves testing;
however, in this research (Swaen, 2018), I used the framework to review my hypotheses
in the differences between male and female and symptoms and the severity of symptoms
with chronic Lyme disease. According to findings from a prospective cohort study of 77
patients in a 2012 study, females with Lyme disease displayed more clinical symptoms
than males and were less likely to seroconvert following treatment (Worcester, 2012).
These findings suggest to us that there may be a difference between how males and
females respond to infection with Lyme disease (Crowder, 2012). Also noted by
Crowder, findings emphasized the need for additional research on sex-based differences
in the effects of Lyme disease, which have not been thoroughly explored in Lyme disease
or in other infectious diseases. Figure 1 outlines the framework for this research below.
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Number of Symptoms of Chronic
Lyme Disease

SEX –

Independent Variable
Male/Female
Level of Severity of Symptoms of
Dependent
Lyme Disease
Variable
Independent Variable
Figure 1. Example of GAM model.
Overview of Literature Review
Lyme disease is a vector-borne infectious disease. The name Lyme disease is
more specific to findings based on a group of children infected in Lyme, CT, in the late
1970s (Dimeo-Ediger, 2017). I briefly review the history of Lyme disease to aid in
understanding an expanding epidemic in the world today. I also discuss published
literature on how chronic Lyme disease has been shown to be present disproportionately
in females more than males. Similarly, I explore literature covering sex bias in medicine
in this section of the chapter, as sex biases arise when diagnosis rests on sameness in
symptoms, severity, and treatment between males and females.
I explain the confusion between sex and gender when infectious disease affects
each stage of the human life cycle, as in age groups. I discuss the literature that explored
issues relating to family history of Lyme disease and health-related quality of life in
chronically ill individuals (male and female) diagnostically positive for Lyme disease.
Finally, the literature-based evaluation of chronic illnesses, as the result of infectious
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diseases, I describe its effect on social and economic burdens, along with differences
between sexes over their lifecycle.
History of the Lyme Disease Epidemic
Lyme disease is the leading vector-borne infectious disease in the world
(Langhoff, 2011). The disease is transmitted to the host by a group of corkscrew-shaped,
gram-negative spirochetes called Borrelia burgdorferi “sensu lato” (or “s.l.”, meaning
broad sense and abbreviated as Bb.; Langhoff, 2011). Borrelia burgdorferi is a
genospecies that contains four groups consisting of several strains (Langhoff, 2011).
Lyme disease has been a known disease for several decades, but in the past 8 years, Lyme
has emerged as an issue of cultural and medical relevance widely discussed by
practitioners and nonpractitioners (Dimeo-Ediger, 2017). Lyme disease is now the fastest
growing vector-borne disease in the world, described by many researchers as a distant
cousin of the syphilis spirochete (Langhoff, 2012). The disease may have spread from
Europe to the United States in the early 1900s, but health experts only recently
recognized Lyme disease as a distinct illness (News-Medical.Net, 2009). Reported cases
seem to have surfaced beginning in Europe as early as the late 1800s, followed by U.S.
cases from the late 1940s to the early 1950s, with a cluster of arthritis cases emerging in
Connecticut during the late 1960s (Langhoff, 2011). In the late 1800s in Europe, Lyme
disease was referenced as a rash of the hands (Horowitz, 2017). Some medical
practitioners described Lyme disease as a skin lesion (Liotta, 2014). Furthermore, reports
from Europe and the United States indicated the same lesions as part of a condition called
Bannwarth syndrome, including radiculitis, Bell’s Palsy, and meningitis (Halperin, 2015).
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In 1909, Afzelius described the disease as an expanding ring-like rash, and 10 years later
linked the presence of a rash to joint problems caused by a tick’s bite (Horowitz, 2017).
In 1922, the disease was found to align with neurological problems, and in 1930, with
psychiatric disturbances with arthritis symptoms (Horowitz, 2017). By 1965, Robbin
described how expanding circular rashes seemed to respond to penicillin treatment
(Horowitz, 2017). Five years later, Wisconsin dermatologist Scrimenti published the first
report of an erythema chronicum migrans rash in the United States (Horowitz, 2017).
Yet, by 1977 in rural Connecticut, all these details and symptoms were not connected
with individuals who were ill. Steere, a Yale rheumatologist, reported symptoms
including fever, headache, and migratory joint pains, as well as multiple cardiovascular
and neurological abnormalities (Horowitz, 2017). In the 30 years since Lyme disease was
identified, in addition to the bacterial infection that would be known as Lyme disease,
other species of Borrelia were identified and along with B. burgdorferi sensu stricto,
were collectively classified as belonging to the Borrelia burgdorferi sensu lato complex
(Smith, 2017).
Lyme disease is a complicated illness linked to larger groups of the species of
Borrelia bacteria (Langhoff, 2012). Yet, many species of Borrelia exist throughout the
world (Langhoff, 2012). The etiologic agent for Lyme disease in the northeast United
States is a bacterium that belongs to a group of spirochetes, identified by Burgdorfer from
the National Institute of Health, while studying ticks on eastern Long Island (Horowitz,
2017), leading to the species of Borrelia subsequently being named Borrelia burgdorferi
(Horowitz, 2017). Worldwide, more than 20 Borrelia species have been identified, all
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associated with Lyme or Lyme-like disease in humans (K. Smith, 2017). Borrelia
burgdorferi sensu stricto is the predominant group of Lyme-disease strains detected in
individuals from the United States and Canada, with Borrelia garinii and Borrelia afzelii,
in addition to Borrelia burgdorferi sensu stricto strains, detectable in individuals from
other countries (Langhoff, 2012).
Documented Lyme Disease Symptoms
Lyme disease is transmitted by the bite or blood-sucking action of an insect, and
ticks are commonly mentioned for Lyme-disease transmission (Langhoff, 2012).
Langhoff (2012) indicated that many other insects can transmit the Bb spirochete. Lyme
disease has three recognized stages: the first, the Early Lyme disease stage (Nordqvist,
2016) can last for several days, and sometimes is present with an erythema migrans (or
bull’s eye) rash (Nordqvist, 2016). The second stage, Early Disseminated Lyme, may last
for several weeks to months after initial infection. Symptoms in this stage include facial
paralysis/Bell’s palsy, meningitis, painful headaches, a stiff neck, swelling of large joints
such as the knees, numbness, shooting pains in the arms and legs, or palpitations or
abnormal heartbeat (Nordqvist, 2016). The underlying denominator for most chronic
illnesses, such as Lyme disease, is inflammatory symptoms, and these symptoms all have
an element of inflammation (Horowitz, 2017). The third stage, Late Disseminated Lyme,
can last for weeks, months, and even years after initial infection. A symptomatic episode
during this stage may include arthritis, difficulty concentrating, unrestful sleep, memory
loss or cognitive impairment, and tingling or numbness in the hands or feet (Nordqvist,
2016).
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Some individuals may have an initial manifestation of the Lyme disease infection
at the chronic or late stage, possibly due to inaccurate testing or misdiagnosis (Nordqvist,
2016). Horowitz (2017) developed a more comprehensive list of all possible symptoms of
Lyme disease, especially in individuals who failed classical treatments. This list built on
treatment of Lyme disease, associated coinfections, and overlapping causes that can lead
to MSIDS. Lyme disease symptoms include unexplained fevers, sweats, chills or
flushing, unexplained weight change (loss or gain), fatigue or tiredness, unexplained hair
loss, swollen glands, sore throat, testicular pain in males, and pelvic pain in females
(Horowitz, 2017). Irritable bladder or bladder dysfunction, general dysfunction or loss of
libido, upset stomach, change in bowel function (constipation or diarrhea), chest pain or
rib soreness, shortness of breath, cough, heart palpitations, pulse skips, heart block, any
history of heart murmur or valve prolapse, joint pain or swelling, stiffness of the joints,
neck, or back, and muscle pain or cramps are also listed as common symptoms of Lyme
disease (Horowitz, 2017). Twitching of the face or other muscles, headaches, neck
cracks, neck stiffness, tingling numbness, burning or stabbing sensations, facial paralysis
(Bell’s palsy), eyes/vision issues (double, blurry, and floaters), ears/hearing problems
(buzzing, ringing, and ear pain), increased motion sickness, vertigo, lightheadedness,
wooziness, poor balance, difficult walking, tremors, confusion, difficulty thinking,
difficulty with concentration or reading, forgetfulness, poor short-term memory,
disorientation (getting lost and going to wrong places), difficulty with speech or writing,
mood swings, irritability, depression, disturbed sleep (too much or too little or early
awakening), and exaggerated symptoms or worse than normal symptoms that appear
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similar to a hangover from alcohol are also part of the common symptoms observed
among individuals with Lyme disease (Horowitz, 2017). A number of these symptoms
occur in conditions other than Lyme disease, so they should not be considered hallmark
symptoms of Lyme disease (Citera et al., 2017). Many conditions can yield symptoms
that might be mistaken for Lyme disease (Citera et al., 2017).
Borrelia bacteria attack specific areas or organs of the body (Horowitz, 2017).
The eye, brain tissue and glial cells, the heart, collagen, skeletal muscle fibers, and the
synovial membrane that surrounds the joints are known organs or body tissues that are
vulnerable to Borrelia attack upon infection (Horowitz, 2017). Early-stage Lyme disease
is typically characterized by erythema migrans, a bull’s eye rash that appears 3 to 14 days
after a tick bit at the site when an individual has been bitten (CDC, 2015a; Grisanti, 2015;
E. Shapiro, 2014). In a study of more than 6,000 individuals diagnosed with Lyme
disease, researchers found that only 17% of participants recalled having erythema
migrans (Lymedisease.org, 2015). Individuals will not often know they have been bitten
by an infected tick, and most individuals do not understand that Lyme disease can also be
transmitted by contact with body fluids such as urine, tears, semen, contaminated blood
and breast milk, or even mites, spiders, mosquitoes, fleas, and biting flies (Doyle, 2011).
Most people believe they might have Lyme disease when they present with symptoms.
Other symptoms of early stage Lyme disease include fatigue, chills, fever, headache,
joint, paint, and swollen lymph nodes (Auwaerter, 2015; CDC, 2015a). The
overwhelming realization of Lyme-disease symptoms makes the diagnosis of the disease
very difficult, complex, and problematic (Auwaerter, 2015; Lymedisease.org, 2015).
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Lyme disease is often misdiagnosed (Grisanti, 2015; Lymedisease.org, 2015).
Results from the Lymedisease.org (2015) study showed that Lyme disease was initially
misdiagnosed as a mood disorder in 59% of participants. Misdiagnosis as chronic fatigue
syndrome was in 55% of cases and 49% of cases as fibromyalgia (Lymedisease.org,
2015). Lyme disease is commonly misdiagnosed as psoriatic arthritis, rheumatoid
arthritis, motor neuron disease, multiple sclerosis, Hashimoto’s thyroiditis, amyotrophic
lateral sclerosis, systemic lupus erythematosus, discoid (cutaneous) lupus, drug-induced
lupus, and neonatal lupus (Auwaerter, 2015; Lymedisease.org, 2015).
Diagnostics Testing for Lyme Disease
In October 1994, the Dearborn Conference, the Second National Conference on
Serologic Diagnosis of Lyme Disease, was sponsored by the CDC, the Association of
State and Territorial Public Health Laboratory Directors, the Michigan Department of
Health, US Food and Drug Administration, the National Institute of Health, the Council
of State and Territorial Epidemiologists, and the National Committee for Clinical
Laboratory Standards (Langhoff, 2012). The purpose of the conference was to establish
surveillance-case definitions and criteria for reporting emerging Lyme-disease cases to
the CDC, as well as to standardize laboratory diagnostic tests to detect Lyme infections.
Accuracy of diagnostic testing depends heavily on the sensitivity and specificity of the
individual test, which varies substantially by manufacturers’ approach (Langhoff, 2012).
Strains from other areas of the United States and the rest of world, including those
which cause neurologic, skin, cardiac, or other manifestations of Lyme disease, were
excluded from the Dearborn’s standardization criteria (Langhoff, 2011). The CDC
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recommended a two-tier system of diagnostic testing that included the ELISA diagnostic
test followed by the western-blot test for Lyme disease. Yet individuals are unlikely to
have their Lyme-disease infection detected by these tests if their infection strain was
excluded from the test probes (Horowitz, 2017). Thus, the recommended two-tier system
is still problematic and may not produce positive test results, especially given that some
strains are excluded from the test-probe standardization (Horowitz, 2017).
As symptoms present differently for each individual resulting from several
different factors, a standardized diagnostic test has not been conclusively developed
(Auwaerter, 2015; CDC, 2015a). If there is no case definition or definitive laboratory test
to identify individuals with a diagnosis of chronic Lyme disease, systematic clinical
evaluation is difficult. Diagnosis often rests entirely on the clinical judgment of a Lymeliterate physician (Wormser & Shapiro, 2009). That said, the western-blot banding
pattern for antibody proteins in the serologic test has been found to be of some utility.
This test is measured in kilodaltons (kDa), (Langhoff, 2012). The bands are separated and
recorded by molecular weight and expressed in kDa. The banding pattern of 31kDa
represents the organism’s outer surface protein A or 34kDA of the outer surface protein
B.
Another test that has become the standard to diagnose Lyme disease is the
IGeneX western-blotting method (Mayo Clinic Staff, 2018). Figure 2 illustrates an
example of positive results of an IGeneX western-blot test for Lyme disease. Using the
CDC/New York State criteria shown in Figure 2, the IgM western blot is reported as
positive if two of the following bands are present: 23–25, 39, and 41 kDa (Kaplan, 2004).
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In contrast, according to the IGeneX criteria, the IgM western blot test is reported as
positive if two of the following bands are present; 23–25, 31, 34, 41, and 45 kDa. IgG is a
sign of a past exposure to or past infection by the organism (Kaplan, 2004).

Figure 2. IGeneX IgM result band markings.
Note. From What You Should Know About Lyme Disease, by IGeneX, 2017,
http://igenex.com/lyme_disease.htm
When reporting bands, the reporting laboratory marks each band with the
following indicators of intensity, shown in Figure 3.

-

Not present

+

Low

++

Medium

+++

High

+/Equivocal = indeterminate (there, but not as intense as Low)
Figure 3. Sample IGeneX results.
Note. From Interpreting the IgG & IgM Western Blot for Lyme Disease, by M. Kaplan,
2004, http://www.anapsid.org/lyme/wb.html
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Sex Differences and Infection
Despite the potential importance of differences in biological sex for the
transmission, course, and outcome of some infectious diseases, no clear understanding
exists of the implications of the effects of sex on the surveillance of and response to
outbreaks, especially for diseases that are not generally transmitted (WHO, 2007). Sex
(biological) and gender (sociocultural) factors are important predictors or determinants of
health outcomes (Day et al., 2016). Infectious diseases rarely affect males and female
equally, despite demographic sex ratios (Guerra-Silveira & Abad-Franch, 2013). Thus, it
is critical to integrate sex and gender considerations throughout the research process to
produce the best possible health outreach, facilitate optimal health-promotion measures,
and improve the target population’s quality of life (Day et al., 2016).
Most autoimmune diseases are more frequent in females than in males (RegitzZagrosek, 2012). For instance, systemic lupus erythematosus is more frequent in females
of reproductive age, as serum estrogen concentration affects its severity (RegitzZagrosek, 2012). Sjögren syndrome is also more frequent in females, again, involving sex
hormones in the pathophysiology. Fibromyalgia, a poorly understood disease, is more
frequent in females than in males, as is rheumatoid arthritis. Most interestingly, females
experience a significant diagnostic delay for rheumatic diseases in comparison to males
(Reitz-Zagrosek, 2012).
Wormser and Shapiro (2009) investigated the implications of sex on chronic
Lyme disease. The researchers compiled data on sex in this cross-sectional study, based
on a systematic review of published studies of antibiotic treatment in U.S. individuals
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with post-Lyme-disease syndrome (n = 184) or chronic Lyme disease (n = 490), and on
cases of adults with Lyme disease reported to the CDC from 2003 to 2005 (n = 43,282).
Study results showed that individuals with chronic Lyme disease were significantly more
likely to be females than were individuals diagnosed with either Lyme disease or with
post-Lyme disease syndrome (Wormers & Shapiro, 2009). Medical personnel must
therefore consider the needs of both sexes, as sex influences health outcomes.
Sex can also modify behavior as a function of certain hormones, such as
testosterone, which causes aggressive behavior associated with risk-seeking and
neglecting personal health or behaviors (Denson, O’Dean, Blake, & Beames, 2018). Sex
differences may lead to genomic and epigenetic modifications (Reitz-Zagrosek, 2012),
and these modifications and their physiological effects are different in males and females.
Also, sex hormones modify DNA repair and epigenetic mechanisms (Reitz-Zagrosek,
2012). The role of sex must be incorporated in research and health care practices, due to
the biological significance of sex with infectious diseases (Reitz-Zagrosek, 2012).
The murine model on the Borrelia hermsii infection pattern shows that males
have a significantly higher initial peak level of spirochetemia than females (Strle et al.,
2013). Another example of a single-center population-based study of children with Lyme
neuroborreliosis showed that facial nerve palsy was a more common symptom in girls
than boys, whereas headaches or neck stiffness was more common in boys than girls
(Tveitnes & Oymar, 2015). The proportion of children with headache and neck stiffness
did not differ significantly between sexes, but headache or neck stiffness as the only
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symptom of Borrelia hermsii infection was statistically significant in boys but not in girls
(Tveitnes & Oymar, 2015).
Autoimmune diseases are more prevalent in females than males (Whitacre, 2001).
Sex-based differences, if present in the host immune response upon infection of Lyme
disease, may be revealed with in-depth analysis of the innate and adaptive cellular
elements mobilized during the early and late manifestations of Lyme disease (Rebman et
al., 2015). Many autoimmune diseases show a female bias (Rebman et al., 2015). Indeed,
basic immune responses differ between females and males and it is notable that females
have higher absolute numbers of CD4+ lymphocytes relative to males, which likely
contributes to the increased responses observed (Whitacre, 2001).
With Lyme disease, reinfection in females is common (McClelland & Smith,
2011). A study of postmenopausal females who experienced recurrent Borrelia
burgdorferi infection revealed increased numbers of cells spontaneously secreting
interferon-c, interleukin-4, and interleukin-10 (Jarefors et al., 2006). These ratios and
responses are opposite to the T-helper-1 cell dominant response necessary for successful
clearance of the B. burgdorferi infection (Jarefors et al., 2006). Sex steroids also have
indirect effects that must be considered in Lyme infection (Jarefors et al., 2006). Sex
hormones modulate the hypothalamic-pituitary adrenal axis, which in turn modulates the
stress response, as oophorectomy results in decreased corticosterone concentrations,
when orchiectomy enhances the corticosterone response (Whitacre, 2001). Female
species in the animal kingdom, including humans, have higher corticosterone-cortisol
concentrations than males (Whitacre, 2001). In addition, glucocorticoids suppress the
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production of sex hormones and the corresponding actions of these hormones in tissues
(Bereshchenko, Bruscoli, & Riccardi, 2018). The sharp spike of corticotropin-releasing
hormone and cortisol at parturition, or childbirth, undoubtedly contributes to the decline
of estrogen postpartum. The discovery of an estrogen-response factor in the promoter
region of the gene-encoding corticotropin-releasing hormone suggests that these two
hormone systems are interregulated. Therefore, interactions between the sex hormones,
hypothalamic-pituitary adrenal axis, and immune-system responses are complex and
intricate, and must be considered when Lyme disease is suspected. Based on this
biological network and interactions, all known intrinsic factors associated with this
interactive relationship must be considered when evaluating the effects of sex differences
in autoimmunity (Whitacre, 2001). Lyme disease is still a complex infection that is
slowly becoming more identifiable than before, and so much about the responses from
infection, inflammation, and immune dysfunction is still unknown (Rebman et al., 2015).
Although Lyme disease is an autoimmune condition that causes an autoimmune
response in the body, it can also mimic, and therefore “cause” other autoimmune diseases
(Schneider, 2015). Many autoimmune diseases differ in their clinical presentation
between males and females (Whitacre, Reingold, & Looney, 1999). The predominance of
autoimmune diseases among females suggests that biological sex hormones may
modulate susceptibility (Whitacre et al., 1999). Although sex differences in autoimmune
disease are well recognized, sex dimorphism in the immune response and the importance
of sex hormones in promoting differences between males and females needs further study
(Whitacre et al., 1999).
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Rebman et al. (2015) also explored the effects of sex on the pathology, diagnosis,
and treatment of Lyme disease. The researchers presented a detailed outline of the
prevalence of early Lyme disease for sexes with late Lyme disease, discerning that
objective neurologic or rheumotologic conditions were reported more often in males than
in females (Rebman et al., 2015). In contrast, the syndromes of more tenuous and
complex origins, known as chronic Lyme disease or posttreatment Lyme disease
syndrome, appear more commonly in females than in males (Rebman et al., 2015).
Females with chronic manifestations of Lyme disease may suffer instead from a
severe immune response brought on by the illness because they are often told they suffer
from a variety of other illnesses including depression, rheumatoid arthritis, fibromyalgia,
and chronic fatigue syndrome, or unexplained medical symptoms (Cameron, 2016).
Researchers from Johns Hopkins University School of Medicine suggested that ongoing
symptoms may be blamed, in part, on an immune response (Aucott et al., 2016). They
also speculated that high CCL19 chemokine (a signaling protein secreted by cells to
simulate the attraction of white blood cells to the place of infection) elevations have been
reported in immune illnesses, and possibly a reflection of ongoing, immune-driven
reactions suggesting that persistent bacteria and/or spirochetal antigens after antibiotic
therapy may advance the disease (Aucott et al., 2016).
Severity of Lyme Disease Symptoms
Researchers compared the severity of chronic Lyme disease with other chronic
conditions qualitatively, using an online survey of 3,090 subjects suffering from chronic
Lyme disease and clinically diagnosed with symptoms persisting 6 months following
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antibiotic treatment (Johnson, Wilcox, Mankoff, & Stricker, 2014). Individuals with
confirmed chronic Lyme disease showed a significantly impaired health-related quality of
life and used healthcare services more compared to the general population and
individuals with other chronic illness (Johnson et al., 2014). Researchers scored severity
using the CDC Health-Related Quality of Life 9-item metric, which includes a 4-item
Healthy Days Core Module and a 5-item Healthy Days Symptoms Module, shown in
Figure 4 (Johnson et al., 2014).

Figure 4. Healthy days symptom module.
Note. From Severity of Chronic Lyme Disease Compared to Other Chronic Conditions: A
Quality of Life Survey, by L. Johnson, S. Wilcox, J. Mankoff, & R. Stricker, 2014,
https://doi.org/10.7717/peerj.322
The overall comparative health status of individuals with long-term or chronic
Lyme disease showed that greater time to diagnosis and greater time since infection
significantly correlated with poorer self-reported health status (Johnson et al., 2014).
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Chronic illnesses account for 84% of healthcare costs, and those with chronic illnesses
are the greatest users of healthcare services (G. Anderson, 2010). Furthermore, the costs
for individuals with an activity limitation are roughly double those of individuals without
an activity limitation (G. Anderson, 2010). Compared with the general population,
individuals with chronic Lyme disease were five times more likely to visit doctors and
health care professionals and more than twice as likely to be seen in an emergency
department. In addition, they were almost twice as likely to stay overnight in a hospital
and roughly six times more likely to receive or pay for home care visits (Johnson et al.,
2014).
In an ongoing chronic-Lyme-disease quality of life study, MyLymeData2018,
which continuously gathers data on symptom severity for individuals with diagnosed
chronic Lyme disease. MyLymeData compares symptoms to the severity and quality of
life of individuals suffering from other chronic diseases (Lymedisease.org, 2018a). Of
chronic Lyme disease individuals, 72% reported fair or poor health status compared to
16% of the general population. This frequency significantly exceeds that of other chronic
diseases, with congestive heart failure (62%) and fibromyalgia (59%) being the closest
((Johnson et al., 2014). Individuals with chronic Lyme disease reported an average of
three severe or very severe symptoms, with 13% reporting at least one symptom and 63%
reporting two or more symptoms as severe or very severe (Johnson et al., 2014). This
finding is at odds with IDSA guidelines, which view these symptoms as no more than the
“aches and pains of daily living” and therefore, the poor health status conforms with the
severity of symptoms reported (Johnson et al., 2014).

49
Another numeric approach to score the severity of symptoms of patients with
Lyme disease is the Nutech functional score. This 43-point positional (every symptom is
subgraded and each alternative gets some points according to its position) and directional
(moves in direction bad to good) scoring system was developed by Nutech Mediworld
(Shroff & Hopf-Seidel, 2018). The Nutech Functional Score grades each symptom from 1
to 5 in the direction from BAD → GOOD (Shroff & Hopf-Seidel, 2018). Originally
developed in 2004 as a numeric scale to score symptoms of cerebral palsy, the scale was
modified for Lyme-disease symptoms in 2017 (Shroff & Bharthakur, 2015).
Summary
The reviewed literature underscored how sex hormones play a role in the genesis
of autoimmunity (Ackerman, 2006). The distinct differences between males and females
in the incidence of infections, the severity of disease, and the likely outcome are a
consequence of sex-related differences in immune-cell composition and activation
following exposure to a pathogen (Galligan & Fish, 2015). Future research may provide a
therapeutic approach that can alter disease pathogenesis, rather than targeting disease
sequelae (Ackerman, 2006). Alternatively, sex-based differences in the host immune
response initiated in Lyme disease may emerge with more in-depth analysis of the innate
and adaptive cellular elements that are mobilized during early and late manifestations of
Lyme disease (Rebman et al., 2015). Many autoimmune diseases show a female bias and
several lines of evidence show that autoimmune processes are a component of Lyme
disease (Rebman et al., 2015). The awareness that males and females differ in their
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response to specific pathogens and to treatments for infectious diseases may yield sexspecific personalized treatments (Klein & Roberts, 2015).
In this study, I presented an analysis of sex differences using the tools of the
GAM for emerging infectious diseases. This analysis showed the relationship between
the sex of the individuals and the severity of their Lyme-disease infections, as a
theoretical foundation. The matrix comprised an x-axis signifying Levels of Analysis
(confirmed chronic Lyme disease) and a y-axis for Categories of Analysis (sex—
male/female). Limitations in the data set precluded the incorporation of some potential
confounders in this research analyses that are unknown in the data set used for this
research.
These two hypotheses showed that current treatments for infectious diseases are
not sex-based, thus forming the basis of the conceptual framework. This conceptual
framework provides evidence of a new-concept of sex-based medicine that considers the
needs of appropriate treatment and therapies for males and females. Researchers at Johns
Hopkins University (2018) performed a study that showed evidence of severe and
lingering symptoms in some individuals following treatment of Lyme disease. PTLDS
causes severe symptoms in the absence of a clinically detectable infection. Findings from
this research show the need for more accurate identification of these individuals, possibly
due to delayed diagnosis and exposure to inappropriate antibiotic and steroid treatment
prior to receiving appropriate treatments (Johns Hopkins Medicine, 2018).
The known etiological agent of Lyme disease is accompanied by one or more
bacterial, viral, parasitic, or fungal infection (Horowitz, 2017). Horowitz defined chronic
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Lyme disease, treated or not, as an MSIDS because symptoms can linger after initial
infection, further explaining how Lyme disease is ultimately a clinical diagnosis. The
lingering symptoms described by Aucott et al. (Johns Hopkins Medicine, 2018) need to
be identified and addressed in subsets of individuals for more accurate identification. The
research approach for this project provided types of subsets as sex, defined as male and
female at birth. The HMQ, created by Horowitz, validated and published with Citera et
al. in 2017, was the basis for this study, describing the gap in the identification of Lyme
disease between males and females, regardless of age. I describe the HMQ further in the
section describing the method used for data collection.
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Chapter 3: Research Method
Introduction
As noted in Chapter 1, I designed this study to investigate the epidemiologic
impact of sex-based differences of chronic Lyme disease. Specifically, this study entailed
a comparative inquiry to explore differences between males and females on their Lymedisease symptomatology. The key variables investigated for the comparative assessment
were biological sex (male or female) and chronic Lyme condition symptomatology. I
describe the methodology used to meet the goals of this current study in this chapter. This
chapter includes the research design, research method, sampling method, data-collection
strategies, and statistical approach.
Research Design and Rationale
The research design selected for this study was a comparative cross-sectional
study design. In a cross-sectional comparative study design, selected participants in two
different groups are compared on one or more variables of interest from data gathered at
one point in time (Jadhav, 2016). In cross-sectional studies, researchers evaluate the
relationship between variables using statistical analyses; however, cause and effect
relationships cannot be definitively determined given that temporality (timing or
duration) is not always clear (Grand Canyon University, 2018; Thiese, 2014). For this
study, the key variables under investigation are sex (male and female), Lyme-disease
symptoms, and the severity of those symptoms. Biological sex served as the predictor
variable, and Lyme-disease symptom, and severity of symptoms were the dependent or
criterion variables.
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RQ1 was What is the relationship between biological sex and the frequency of
symptoms of individuals with confirmed chronic Lyme disease? To address RQ2, the
difference in the symptoms of Lyme disease were assessed based on sex to determine
whether the symptoms are sex-based. Additionally, RQ3 included in the study the
severity of symptoms identified for classification to appraise whether the severity of
symptoms is sex-specific by analyzing the significance of the severity of Lyme symptoms
between males and females.
Lyme disease is an infectious disease investigated in this study’s scope to provide
better understanding of how to effectively address sex-driven pathological differences
and manage the disease. The decision to use a cross-sectional comparative quantitativemethod design was based on the objective to measure associations among sex differences
with Lyme-disease infection. For that purpose, the secondary data source was a
questionnaire approach used with a cross-sectional design and quantitative method,
which provided the data used in this study analysis. The secondary data consisted of
responses to the HMQ, based on the secondary data’s dictionary codebook, obtained from
the data source. The HMQ, designed and validated by Horowitz and colleagues, is
intended for use in the clinical assessment and care of individuals with Lyme disease to
provide information about an individual’s Lyme-disease diagnosis and symptom
assessment (Citera et al., 2017).
The full list of the 38 symptoms from the HMQ were considered in this study. As
noted in that section, a count of the number of symptoms was calculated by summing the
number of symptoms presented (i.e., possible scores could range from 0–38 symptoms).
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Severity of each symptom was measured on a 4-point Likert-type scale ranging from 0
(absence of symptom) through 3 (severe); further details are provided in the symptom
index section.
According to the CDC, as of 2017, Lyme disease sickens approximately 300,000
Americans per year, making the disease more common than the West Nile virus or any
other illness transmitted by insects or arachnids (Ginsberg et al., 2017). Lyme disease can
have a long latency period between exposure and disease manifestation or diagnosis,
regardless of the sex of those infected and their location of residence (LaMorte &
Sullivan, 2016). Patients’ current residence may not be the point of acquired infection
and may not be a collected data point, as the diagnosis and confirmation of their Lyme
infection can happen long after initial infection. Therefore, the onset or duration of
infection is not a variable for consideration nor is it a confounding variable, as it is not
relevant to the differences experienced between males and females.
Methodology
Population
The data set used for this investigation were gathered by Horowitz through the
HMQ for Lyme disease. The data set contains questionnaire data on 82 variables from a
subset of Horowitz’s total population of 1,190 participants. Horowitz created the MSIDS,
which was validated for use as a screening tool in 2017 (Citera et al., 2017). Horowitz is
medical director of the Hudson Valley Healing Arts Center in Hyde Park, New York
(Bay Area Lyme Foundation, 2018). This location is an integrative medical center that
combines classical and complementary approaches in the treatment of Lyme disease and

55
other tick-borne disorders. Horowitz has treated more than 12,000 individuals with
chronic Lyme disease in the last 29 years, with patients coming from all over the United
States, Canada, and Europe (Bay Area Lyme Foundation, 2018).
I requested the Hudson Valley Healing Arts Center, in Hyde Park, New York,
make available to me a data set drawn from a population of individuals with chronic
Lyme disease. I contacted Dr. Freeman, head of the Horowitz research group, as the lead
investigator for the 2017 empirical validation of the MSIDS questionnaire study, and
Citera for a data set that fits the parameters and variables of the research in this study. I
obtained a data set from Horowitz for use in this project, gathered through the HMQ for
Lyme disease. Horowitz provided the deidentified data for this study, and the data set was
used for analyses in this current study. This data set was used as a secondary data source
and confidentiality agreements were signed with the academic research group at the State
University of New York (SUNY)-New Paltz, NY.
Sampling and Sampling Procedures
In the secondary data source, data accrued using the MSIDS questionnaire. The
inclusion criteria were that respondents must be either male or female, age 18 or older,
who have been confirmed with a diagnosis of Lyme disease. The demographic
characteristics in the data set include individuals living in the United States who were
previously treated or are currently being treated for Lyme disease. The specific variables
examined from the data set were the sex of a respondent (male or female) and the number
of 38 different symptoms and severity of those 38 symptoms of Lyme disease. Data
accrued from medical records, specific questionnaires, confirmation of Lyme disease,
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age, residence, and sex of the individual listed in the data set. As the data used in this
project were previously collected for research publication by Citera, Freeman, and
Horowitz 5 years prior to this current study, Horowitz approved the use of the data set
and Citera provided the confidentiality agreement for signature before I accessed the data
set. The data set included 1,190 patient records of whom 236 have documented evidence
of Lyme disease and met the criteria for a clinical diagnosis, 568 healthy individuals with
no confirmed diagnosis of Lyme disease, and 386 individuals with missing or incomplete
data (Citera et al., 2017). The data set of the 236 participants with confirmed Lyme
disease was the data set approved for my use in this research. Institutional Review Board
(IRB) approval was granted June 2, 2014 and data collection took place between 2014
and 2016 for the 2017 publication of the validation study (Citera et al., 2017).
Instrumentation and Operationalization of Constructs
The source of the secondary data set used in this study was the HMQ data
collected from the 2017 validated MSIDS questionnaire, fielded by Horowitz. This data
set consisted of four sections, with each section providing clinical diagnostic information
about an individual’s likelihood of having Lyme disease or other tick-borne illnesses
(Citera et al., 2017). The variables from their data set that corresponded for use in my
research are biological sex (male and female), the MSIDS 38 symptom checklist, rated for
frequency of symptoms as 0 (never), 1 (sometimes), 2 (most of the time), and 3 (all of the
time), and the severity of symptoms rated 0 (never), 1 (sometimes), 2 (most of the time),
and 3 (all of the time; Citera et al., 2017). It is important to note that the variable sex is
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defined as male or female at birth. All participants in the data set self-identified their
biological sex as either male or female.
The 38 symptoms from the checklist follow: unexplained fevers, sweats, chills, or
flushing; unexplained weight change (loss or gain); fatigue, tiredness; unexplained hair
loss; swollen glands; sore throat; testicular pain/pelvic pain; unexplained menstrual
irregularity; unexplained breast milk production, breast pain; irritable bladder or bladder
dysfunction; sexual dysfunction/loss of libido; upset stomach; change in bowel function
(constipation or diarrhea); chest pain or rib soreness; shortness of breath/cough; heart
palpitations, pulse skips, heart block; history of heart murmur or valve prolapse; joint
pain or swelling; stiffness of the neck or back; muscle pain or cramps; twitching of the
face or other muscles; headaches; neck cracks or neck stiffness; tingling, numbness,
burning or stabbing sensations; facial paralysis (Bell’s palsy); eyes/vision—double,
blurry; ears/hearing—buzzing, ringing, ear pain; increased motion sickness, vertigo;
lightheadedness, poor balance, difficulty walking; tremors; confusion, difficulty thinking;
difficulty with concentration or reading; forgetfulness, poor short term memory;
disorientation; getting lost, going to wrong places; difficulty with speech or writing;
mood swings, irritability, depression; disturbed sleep—too much, too little, early awake;
exaggerated symptoms or worse hangover from alcohol (Horowitz, 2013).
Sample Size and Power Analysis
The need for clarity on having sufficient data on individuals with Lyme-disease
confirmed by Lyme-literate practitioners is important in maintaining statistical power to
minimize the possibility of a Type I (false positive) or Type II error (false negative).
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The statistical technique used for this analysis was a multivariable analysis for the
symptoms by sex and then analyzing severity specifically using negative binomial
regression. G*Power was used to test whether the actual sample of 236 was large enough
to have adequate power to detect differences between the sex groups. To achieve 95%
statistical power, and assuming a medium effect size of 0.15, an alpha level of 5%, and
five independent variables (i.e., sex, age, race/ethnicity, employment status, and
education), a sample size of 138 individuals would be needed. The formula for multiple
linear regression is as follows:
= exp(ln(ti) + b1X1 + b2X2 + b3X3 + b4X4 + b5X5
where µ = the dependent variable, ti is the exposure to a particular observation, b = the
amount that an independent variable is modified by the regression equation (i.e., the slope
of a regression line), and X is a given independent variable. The G*Power 3.1 program
was used for the sample-size calculation presented in this section of the dissertation. In
the Horowitz data set, 236 individuals met the criteria for inclusion in the study, which is
more than the 210-sample size required by G*Power for a regression and a t test,
respectively.
Data-Analysis Plan
This study required descriptive and inferential statistics to be calculated to address
the dissertation requirements. To do so, the Statistical Package for Social Sciences
(SPSS) was used for statistical analysis. Specifically, descriptive statistics were computed
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for all data. Means and standard deviations were calculated for continuous variables and
percentages and frequencies were computed for categorical variables. Two statistical
techniques were used: an independent samples t test and negative binomial regression.
The t test served as a descriptive analysis to compare the crude differences between males
and females for RQ1 (symptom count), whereas inferential analyses were performed with
the negative binomial model for RQ2 and RQ3. I describe each later in this chapter. As
noted earlier, I used a secondary data source for this study. In many cases, the purpose for
which the secondary data are collected may not be similar or the same as the primary
purpose intended by the secondary users of such data. For this study, the biological sex of
the individual with Lyme disease was the primary independent variable of interest and
the number of symptoms and severity of symptoms were the dependent variables in this
study. I coded the data to ensure these forms of the variables could be achieved. The
following research questions were addressed in this current study.
RQ1: What is the relationship between biological sex and the frequency of
symptoms (see the list of 38 symptoms) of individuals with confirmed chronic Lyme
disease?
H01: No statistically significant relationship exists between biological sex and the
symptoms of individuals with confirmed chronic Lyme disease.
Ha1: A statistically significant relationship exists between biological sex and the
symptoms of individuals with confirmed chronic Lyme disease.
RQ1 is an overarching guide to this project and was analyzed using a t test to
describe the difference in symptoms across the sexes. The goal of this question was to
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describe the dependent variable (a continuous measure), representing the frequency
(never to always) of symptoms. The independent variable is biological sex, a
dichotomous variable. The independent sample t test fits for this analysis method because
it can be used to compare two means across two independent groups. The independent
samples t test is appropriate when the expectation is to see if the mean score of a
continuous dependent variable varies as a function of a dichotomous independent
variable (Ritchey, 2008).
I also checked Levene’s test for homogeneity of variance as part of this test to
determine whether the two groups have roughly the same variance (i.e., homogeneity of
variance) or have different variances (i.e., heterogeneity of variance; Statistics Solutions,
2020). I checked the dependent variable to determine if it is normally distributed, using
the Shapiro–Wilk test. If the normality assumption was in question, a nonparametric test
(such as the Mann–Whitney U test) was used in place of the independent samples t test
(Statistics Solutions, 2018a).
RQ2: Are there differences in the number of symptoms associated with Lyme
disease between adult females compared with adult males diagnosed with Lyme disease?
H02: No statistically significant differences exist in the number of symptoms
associated with chronic Lyme disease between adult females and adult males
diagnosed with chronic Lyme disease.
Ha2: Statistically significant differences exist in the number of symptoms
associated with chronic Lyme disease between adult females and adult males
diagnosed with chronic Lyme disease.

61
A multiple linear regression analysis, in this case a negative binomial regression,
was used to investigate RQ2. Negative binomial regression is appropriate when the
dependent variable is a count variable and there is a mixture of continuous and
categorical independent variables (Hilbe, 2011). In the negative binomial regression
equation, the outcome variable (or y) is a count variable that adds together the number of
symptoms of Lyme disease a respondent has (0 to 38), and b1X1 is the estimated
regression coefficient that quantifies the association between being either male or female
and the outcome variable, adjusting for the impact of several confounding variables in the
regression equation (LaMorte, 2016).
Multivariable analysis is necessary when analyzing infectious diseases that are
influenced by a number of factors that impact an exposed individual’s immunologic
response to the causative agent/pathogen (Katz, 2011). For this analysis, these factors that
were to be considered in the multivariable modeling were age, race/ethnicity,
employment status, and education of each respondent but were not available for analysis
in the data set.
RQ3: Are there significant differences in the severity of symptoms associated
with chronic Lyme disease between adult females and adult males diagnosed
with chronic Lyme disease?
H03: No statistically significant differences exist in the severity of symptoms
associated with chronic Lyme disease between adult females and adult males
diagnosed with chronic Lyme disease.
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Ha3: Statistically significant differences exist in the severity of symptoms
associated with chronic Lyme disease between adult females and adult males
diagnosed with chronic Lyme disease.
RQ3 aimed to examine the differences between males and females in symptom
severity. Similar to RQ2, a count variable was constructed to look at the relationship
between sex and the severity of each symptom when controlling for other factors, as
listed in RQ2. The justification for using this method is the same as with RQ2, which is
“Are there differences in the number of symptoms associated with Lyme disease between
adult females compared with adult males diagnosed with Lyme disease?”
Threats to Validity
A quantitative cross-sectional survey research requires that all variables be
measured simultaneously (Public Health Action Support Team, 2017). Horowitz (2017)
validated the MSIDS questionnaire at the time of Lyme disease testing or confirmed such
testing was performed for each participant. Thus, Horowitz provided the survey and
assessment tools to the individuals simultaneously, which met the requirements for a
quantitative survey research study design.
A limitation in the validity of this study is that no causal inference can be made
for individuals with Lyme disease based on sex and the number and severity of
symptoms. Only a correlational inference can be made, as the data are not experimental
in nature. Correlation is not the same as causality (Creswell, 2009; Glanz, Rimer, &
Viswanath, 2008; Rudestam & Newton, 2015; Szklo & Nieto, 2014).
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Another primary limitation of validity in this study is one shared by all
quantitative survey research, that validity can be a problem with surveys or
questionnaires. Questionnaires tend to be standardized, which can create difficulty in
asking questions other than general ones targeted to a broad range of people. Construct
validity was used to test the reliability of the HMQ. The researchers used this type of
testing to determine correlations with the use of the questionnaire, proving it accurately
differentiated individuals with Lyme disease from those without Lyme disease. Citera et
al. (2017) concluded that the questionnaire measured acceptable levels of internal
reliability using Cronbach’s coefficient alpha and exhibited evidence of convergent and
divergent validity upon the conclusion of the validation study for MSIDS questionnaire
(Citera, et al., 2017). In other words, convergent and divergent validity are both subtypes
of construct validity. Construct validity is a test (i.e., questionnaire) designed to measure
a particular construct (i.e., difference between symptoms and severity of individuals with
Lyme and those without). Convergent validity takes two measures that are supposed to be
measuring the same construct and shows that they are related, whereas conversely,
divergent validity shows that two measures that are not supposed to be related are in fact,
unrelated (Lund Research, 2012).
A cross-sectional design is applied in a study to evaluate the prevalent rather than
incident outcomes and thus excludes people who develop the outcome but die before the
conclusion of the study (Carlson & Morrison, 2009). As explained in Chapter 1, it is
sample bias reflected in the cross-sectional study design that identifies prevalent cases
rather than incident cases. In other words, sample bias is a possible limitation, potentially
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affecting validity due to the size of the sample and without follow-up on the survey data.
Recall bias can be a factor in the collection of the data collection due to self-reporting on
symptoms and their relative severity, for which the researcher cannot adjust. The
measured association in a cross-sectional study is between exposure and having the
outcome rather than to exposure and developing the outcome (Carlson & Morrison,
2009).
One limitation addresses external validity, insofar as no generalization to the
entire U.S. population can be made in this study beyond the specified target population—
individuals with confirmed Lyme disease—because the current study is not an extensive
multisite study. In other words, the residence of participants was not a data point
collected and many survey questionnaires were completed through electronic data capture
through a database website. This study is therefore somewhat limited in generalizability
primarily, based on how useful the results of a study are for a broader group of people.
Additionally, study outcomes are not based on any treatment or interventional study, as
no participants were treated with any specific medication or therapy. The purpose of this
study is not tailored to Lyme-disease intervention because data used were from secondary
sources following Lyme treatment and follow-up with the participants through a
questionnaire survey. The application of a quantitative method was not used to
effectively measure subjective experiences or emotional states of individuals affected by
an outcome or those exposed to a risk factor (DiClemente et al., 2013; FrankfortNachmias & Nachmias, 2008).
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Ethical Procedures
Horowitz granted access to a data set from the 2017 validation study led by
Citera, a professor in the Department of Psychology at the State University of New York
at New Paltz, New Paltz, NY. Freeman, a researcher at Hudson Valley Healing Arts
Center in Hyde Park, NY working with Horowitz, contacted Citera for approval to
provide a data set from their research. The Human Research Ethics Board (the IRB) of
the SUNY-New Paltz provided a confidentiality agreement for my signature and after all
documents were in place, the data set was approved for my use in this research.
The survey component for the 2017 validation study of the HMQ was certified as
exempt on June 2, 2014 (Citera et al., 2017). The application for approval was filed with
the Walden IRB for acceptance of the use of secondary data in the analysis for this
research. Upon approval from the Walden University IRB, the data set was released to
me for use and analyses by the Human Research Ethics Board [the IRB] of SUNY-New
Paltz.
Summary
In this research study, I measured all variables simultaneously. In other words, the
number and severity of Lyme disease symptoms in adult males with confirmed Lyme
disease were compared to adult females with confirmed Lyme disease. In the data set
retrieved from Horowitz’s and Citera’s research databases, all data were made available
for the analyses supporting this research. The goal was to determine whether the null
hypothesis for each posed research question should be rejected, based on the p-value
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level of significance. The results of this study and the conclusions drawn from these
findings are discussed in detail in Chapters 4 and 5, respectively.
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Chapter 4: Results
Introduction
Lyme disease is an illness comprised of multiple infections in addition to the
primary parasitic spirochete infection, Borrelia burgdorferi (Ross, 2018). These other
infections are known as coinfections and can be viral, bacterial, fungal, and parasitic
infections, such as Bartonella, Babesia, Anaplasma, Ehrlichia, and Clostridium difficile
(Berghoff, 2012). Combinations of these chronic coinfections create MSIDS, a term
coined by Horowitz, (lymeactionnetwork.org, 2017). Along with these coinfections are
other factors such as allergies, environmental toxins, and a compromised immune system,
and consequently, a chronic Lyme-disease infection is a multifaceted and complex illness
making the diagnoses and treatment an extremely difficult process (Lyme Action
Network, 2017). Lyme disease is definitively an illness that causes direct and indirect
dysfunction to most body organs and systems, yet is distinct for each individual (Ross,
2018).
I designed this study to investigate the epidemiologic consequence of sex-based
differences of chronic Lyme disease. Sex differences in the pathogenesis of infectious
diseases may reflect variations with immune responses during infection (vom Steeg &
Klein, 2016). This study entailed a comparative inquiry to determine if a statistically
significant difference exists between males and females in chronic Lyme
symptomatology and severity, an area that has received limited attention in previous
research. Sex—being female or male—influences one’s immune responses, contributing
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to variation in the pathogenesis of infectious disease in males and females and the
prevalence of autoimmune diseases (Ruggieri et al., 2016).
The focus of this study was to investigate the research gap based on biological sex
and Lyme disease by exploring the following research questions:
RQ1: What is the relationship between biological sex and the frequency of
symptoms of individuals with confirmed chronic Lyme disease?
H01: No statistically significant relationship exists between biological sex and the
symptoms of individuals with confirmed chronic Lyme disease.
Ha1: A statistically significant relationship exists between biological sex and the
symptoms of individuals with confirmed chronic Lyme disease.
RQ2: Are there differences in the number of symptoms associated with Lyme
disease between females compared with males diagnosed with Lyme disease?
H02: No statistically significant differences exist in the number of symptoms
associated with chronic Lyme disease between adult females and adult males
diagnosed with chronic Lyme disease.
Ha2: Statistically significant differences exist in the number of symptoms
associated with chronic Lyme disease between adult females and adult males
diagnosed with chronic Lyme disease.
RQ3: Are there significant differences in the severity of symptoms associated
with chronic Lyme disease between adult females and adult males diagnosed with
chronic Lyme disease?
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H03: No statistically significant differences exist in the severity of symptoms
associated with chronic Lyme disease between adult females and adult males diagnosed
with chronic Lyme disease.
Ha3: Statistically significant differences exist in the severity of symptoms
associated with chronic Lyme disease between adult females and adult males diagnosed
with chronic Lyme disease.
In this chapter, I describe the secondary data-collection process. review any
modifications of the data collected, provide the methods used for statistical analysis, and
present the results from this research.
Data Collection
The data used for this study were secondary data provided by a clinician
specializing in caring for individuals with Lyme disease. The data include responses to
the HMQ for Lyme disease. The HMQ is a questionnaire used by health care
practitioners as part of the clinical assessment for diagnosing Lyme disease. Citera et al.
(2017) provided a data set from the valuation of the HMQ for Lyme disease. The dataset
included 236 persons with a confirmed Lyme-disease diagnosis from 2014 through 2016.
Of the 236 persons with a confirmed Lyme disease diagnosis, one person had
missing information for one of the symptoms (bowel function), which comprises the
outcome variable for the inferential analyses. Therefore, I excluded this individual from
the analysis, bringing the total sample for this study to 235 individuals who had complete
data for all 38 symptoms.
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Sex and age were the only demographics provided in the final data set. The data
set did have programmed columns for race, employment status, and education, but these
data were not collected to ensure the anonymity of participants, as originally approved by
the SUNY IRB. Although these variables were originally thought to be included in the
data set because the questions were listed in the codebook, once I received the data, I
realized these variables were not collected and thus could not be used for this project.
These variables were not included in any of the research results collected for the HMQ
validation study.
Results
Study Population
In Table 2, the percentages and frequencies for the primary independent variable,
sex, are presented.
Table 2
Sex Frequency of Participants with Confirmed Lyme Disease
Frequency
Female
Male

Percent

195

83.0

40

17.0

Note: N = 235.

The mean age of participants was approximately 48 years old (SD = 13.71). The
mean age was 46–50 and the range of ages was under 20 to over 80. Table 3 provides the
distribution of the sample by age.
Table 4 provides univariate statistics for the count of symptoms and severity of
symptoms. The mean of the severity of symptoms score was calculated by adding all
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scores in the Section 1: Symptom Frequency Score of the HMQ (Horowitz, 2014). If the
score was between 21 and 45, the probability of a tick-borne disorder was high and
indicated the individual should see a health care provider for further evaluation
(Horowitz, 2014). When the results of Section 1 of the HMQ show a high frequency of
symptoms scored, those with a score of 3 are then listed in Section 2: Most Common
Lyme Symptoms of the HMQ. These are those symptoms characterized as high
probability of having Lyme-MSIDS (Horowitz, 2014). The severity score is the
calculated total of those symptoms with a score of 3 per symptom from Section 1:
Symptom Frequency Score. The following section, Section 2: Most Common Lyme
Symptoms Score is where the top common symptoms of Lyme disease are listed. Again,
these are those with a high-frequency score, characteristic of those with a high probability
of having Lyme-MSIDS (Horowitz, 2014). Table 4 shows the main dependent variables
used in the inferential analysis to test the research questions.
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Table 3
Age Distribution/Ranges of MSIDS Data Set
Age range

Frequency

Percent

< 20

10

4.7

21–25

9

3.9

26–30

11

4.6

31–35

15

6.5

36–40

14

6.0

41–45

20

8.0

46–50

60

25.6

51–55

32

13.0

56–60

23

9.8

61–65

24

9.8

66–70

9

3.8

71–75

5

2.0

76–80

2

0.8

> 80

2

0.8

235

100.0

Note: N = 235.

Table 4
Means and Standard Deviations, Scale Variables
Variable

Mean

SD

Median

Range

Count of symptoms
Severity of symptoms
Note: N = 235.

21
35

7.88
17.80

21
33

0–37
0–94
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Hypothesis Testing
To test the hypothesis, a series of interferential analyses were conducted along
with the proper assumptions for each test. Hypothesis testing is organized by research
question.
Research Question 1
The results for RQ1, “What is the relationship between biological sex and the
frequency of symptoms of individuals with confirmed chronic Lyme disease?” are given
below. To first understand the symptomology of Lyme patients, I compared males and
females for each of the 38 symptoms. Fatigue was the most common symptom for
members of both sexes, as seen in Table 5, listed by the most common symptoms among
females.
I used the Shapiro–Wilk statistic to assess whether the data for frequency of
symptoms was normally distributed. The Shapiro–Wilk obtained was 0.985 with df = 235
and a p-value of .017), suggesting evidence of deviation from normality. In addition, I
produced a Normal Q-Q plot to assess normality. For a normal distribution, the points
must be about the same distance from the line in the Normal Q-Q plot shown in Figure 5
(Glen, 2019). I ran parametric independent samples t tests and Mann–Whitney U tests for
the count of symptoms variable.
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Table 5
Frequencies and Percentages for Symptoms by Sex
Males
Fatigue
Disturbed sleep
Stiff neck or back
Neck cracks
Joint pain
Mood swings
Concentration/reading
Forgetfulness
Muscle pain
Headaches
Fevers
Confusion
Upset stomach
Light-headedness
Bowel function
Tingling, numbness
Speech/writing
Shortness of breath
Ears/hearing
Sexual dysfunction
Heart palpitations
Twitching
Motion sickness/vertigo
Weight change
Eyes/vision
Chest pain
Disorientation, getting lost
Bladder
Sore throat
Hair loss
Swollen glands
Tremors
Worse hangover
Heart murmur
Menstrual irregularity
Testicular/pelvic pain
Breast pain
Facial paralysis

Frequency
36
33
32
32
31
30
26
24
30
30
22
27
20
23
19
27
19
24
24
20
19
24
19
15
20
21
13
12
20
9
16
18
12
5
0
12
1
8

Females
Percent
90
82
80
80
77
75
65
60
75
75
55
67
50
57
47
67
47
60
60
50
47
60
47
37
50
52
32
30
50
22
40
45
30
12
0
30
2
20

Note: N = 235; 195 Female participants/40 Male participants.

Frequency
183
172
169
158
156
156
157
154
152
149
146
144
132
130
123
120
120
114
110
109
103
100
100
94
94
92
89
86
85
82
83
63
57
50
41
38
33
26

Percent
93
88
86
81
80
80
80
79
77
76
74
73
67
66
63
61
61
58
56
55
52
51
51
48.
48
47
45
44
43
42
42
32
29
25
21
19
16
13

75

Figure 5. Q-Q plot for count of symptoms.
Table 6 lists the results of the t test. The mean symptom count for females was 21
with a standard deviation of 7.66, whereas the mean symptom count for males was 19
with a standard deviation of 8.81. Results of the independent samples t test were not
statistically significant (t = 1.51; df = 233; p = .133), suggesting no difference between
males and females in the frequency of symptoms of Lyme disease. The Levene’s test of
homogeneity of variance was statistically nonsignificant (F = 1.230; p = .268), suggesting
the data are homoscedastic, meaning “having the same scatter.”
Table 6
T Test for Frequency of Symptoms by Sex

Female
Male
Note. N = 235.

N

Mean

SD

195

21

7.66

40

19

8.81

t

df

Sig

233

.133
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The results of the Mann–Whitney U test were also statistically nonsignificant (U
= 3373.5; p = .178), which suggests no difference emerged between males and females in
the frequency of symptoms of Lyme disease (see Table 7).

Table 7
Mann-Whitney U Test of Frequency of Symptoms by Sex

Female
Male

N

Mean rank

MWU

Sig

195

120

337350

.178

40

104

Note: N = 235, MWU = Mann–Whitney U test.

Research Question 2
The results for RQ2, “Are there differences in the number of symptoms associated
with Lyme disease between adult females compared with adult males diagnosed with
Lyme disease?" were determined using a negative binomial regression model with the
outcome of frequency of symptoms and independent predictors of age and sex. The
Omnibus X2 test, summarized in Table 8, was not statistically significant (X2 = 0.352, df =
2; p = .839), suggesting that the neither of the independent variables of age and sex have
any effect on the number of symptoms per participant, respectively.
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Table 8
Negative Binomial Regression of Number of Symptoms onto the Predictors
Variable

B

SE(B)

p

Intercept

3.004

0.283

0.000

Sex of Respondent (Female)

0.104

0.179

0.560

Sex of Respondent (Male, referent group)

0.000

—

—

0.005

0.853

Age of Respondent (years)

-0.001

Omnibus X2

0.352

0.839

Note. N = 235.

Research Question 3
The results for RQ3, “Are there significant differences in the severity of
symptoms associated with chronic Lyme disease between adult females and adult males
diagnosed with chronic Lyme disease?” appear in Table 9. Table 9 shows descriptive
statistics for males and females in symptom severity. Females have a higher mean
severity score (M = 36.2) than males (30.1).
Table 9
Severity of Symptoms by Sex
Variable

M

SD

Range

Severity of symptoms (Females)

36

17.5

2–94

Severity of symptoms (Males)

30

18.4

0–83

Note. N = 235.

A negative binomial regression model was fit with the outcome of severity of
symptoms and independent variables of age and sex. The Omnibus X2 test, shown in
Table 8, was not statistically significant (X2 = 1.060, df = 2; p = .589), suggesting that age
and sex have no impact on the severity of symptoms (see Table 10).
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Table 10
Negative Binomial Regression of Severity of Symptoms Onto the Predictors
Variable

B

SE(B)

p

Intercept

3.413

0.282

0.000

Sex of Respondent (Female)

0.185

0.177

0.295

Sex of Respondent (Male)

0.000

—

—

Age of Respondent

0.000

0.005

0.974

Omnibus X

2

1.060

0.589

Note. N = 235.

Assumption Tests for Negative Binomial Regressions
Several assumptions that must be met in multiple linear regression: linearity,
homoscedasticity, independence of errors, normality of errors, and multicollinearity
(Allisonn, 1999). The first assumption, linearity, proposes that the relationships of the
variables under investigation are linear in nature. The way to investigate whether this
assumption holds is to check the plot of the regression standardized residuals, or the
Normal P-P plot. As long as a linear trend is evident in the plot, the assumption of
linearity is met (Mertler & Vannatta, 2010). The Normal P-P plot for number of
symptoms as a dependent variable and severity of symptoms as a dependent variable
shows that this assumption was met (see Figures 6 and 7).
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Figure 6. Normal P-P plot of regression standardized residual dependent variable:
symptom count—A count variable of the number of symptoms.

Figure 7. Normal P-P plot of regression standardized residual dependent variable:
severity count—A count variable of the severity of symptoms.
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The second assumption, homoscedasticity, confirms that the degree of random
noise (or error) in the regression equation remains relatively constant or homoscedastic
(Allison, 1999). The Breusch–Pagan Test (Breusch & Pagan, 1979) is essentially a chisquare test for heteroscedasticity. If the value of chi-square is statistically significant, the
data are considered heteroscedastic and corrective measures are required. The Breusch–
Pagan test was statistically non-significant for the severity of symptoms ( c 2 = 0.308, df =
2, p = 0.857) and the number of symptoms ( c 2 = 2.483, df = 2, p = 0.289). This
assumption was met.
The third assumption, independence of errors, confirms that the disturbance terms
in the regression equation are uncorrelated. This assumption is checked with the Durbin–
Watson statistic. The Durbin–Watson statistic ranges from 0 to 4, with a midrange value
of 2. As a general rule, values of the Durbin–Watson statistic closer to 2 indicate
independence of errors; values below 1 and above 3 suggest correlation of errors
(Gujarati, 2003). The Durbin–Watson statistic for the severity of symptoms was 1.878,
and for the number of symptoms was 2.055. This assumption was met.
The fourth assumption, normality of errors, is predicated on the understanding
that all errors are normally distributed in a regression equation. As long as all other
assumptions are met, the violation of this assumption can be discounted (Allison, 1999).
The Shapiro–Wilk Test of the standardized residuals is the test used to check this
assumption (S. Shapiro & Wilk 1965). The value of the test is statistically significant for
the severity of symptoms (0.964, df = 235, p < .001) and the number of symptoms (0.985,
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df = 235, p < .05). This assumption was not met; however, given that all other
assumptions were met, corrective action is unnecessary at this time.
Multicollinearity is not a violation of the assumptions of regression per se;
however, multicollinearity does make it difficult to find statistically significant
coefficients in a regression model (Allison, 1999). Multicollinearity is typically checked
by calculating variance-inflation factors (VIFs). A VIF of 10 or greater typically indicates
potential multicollinearity (D. Anderson, Sweeney, & Williams 2002). All VIFs in all
modes for both dependent variables were under 2.0. This assumption was met.
Summary
This chapter included a summary of the results of this study. No difference
between the frequency of Lyme-disease symptoms, the number of symptoms, or the
severity of symptoms between males and females in this data set. The sex or age of the
participant does not contribute to the outcomes of the participant. Chapter 5 includes the
interpretation of the research findings.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
Historically, sex as a variable in infectious-disease research has been overlooked
(Ingersoll, 2017). Recently however, the biological pathways responsible for sex-based
differences in the manifestations of infectious diseases have begun to be unveiled (van
Lunzen & Altfeld, 2014). The purpose of the present study was to investigate the sexbased differences for chronic Lyme disease. According to the CDC, Lyme disease is the
most prominent of vector-borne disease cases reported each year in the United States,
with a larger number of cases than many other diseases more familiar to the public,
including breast cancer, colon cancer, and human-immunodeficiency-virus infection
(Vector Disease Control International, 2019). Late-stage or chronic Lyme disease can be
the result of failing to properly diagnose and treat the infection early, leading individuals
to experience symptoms weeks, months, or years after the presumed initial infection date
(Vector Disease Control International, 2019).
I performed analyses for this research study using secondary data of symptoms
and related severity of those symptoms between the sexes. The data accrued using the
MSIDS questionnaire developed and validated by Horowitz (Citera et al., 2017). The
study population for this research consisted of 40 males who comprised 17% of the
participant participation, and 195 females, comprising the remaining 83%. All
participants included in the data set were confirmed to have chronic Lyme disease. The
data collected from these participants were anonymous through a web-portal database.
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Therefore, no identifiers such as race, ethnicity, or residence were collected using this
questionnaire.
The purpose of this study was to observe if any differences emerged between the
sexes from this data set of people with confirmed late-stage Lyme disease (chronic Lyme
disease). No statistically significant differences emerged between males and females in
the number or severity of symptoms. In this chapter, I present further interpretation of
these findings and the implications of this research pertaining to the advancement of
knowledge of Lyme-disease research. In addition, I discuss the limitations of this study
and offer recommendations for future research. Finally, I conclude this chapter with a
summary that highlights the key essence of the study.
Interpretation of the Findings
I designed the present research to examine the relationship between the frequency
and severity of Lyme-disease symptoms with patient sex. I discuss the findings in answer
to these research questions and my interpretation of these findings. To the best of my
knowledge, based on a thorough review of the literature, this study is the first to examine
sex differences regarding the type, number, and severity of chronic-Lyme-disease
symptoms, not including diagnostic findings. Therefore, it is not possible to make any
direct comparisons between this study’s results and those of previous studies found in the
literature. Instead, I discuss the study findings in the context of the current knowledge of
chronic Lyme disease in the scientific community.
For this study, I used HMQ data collected from the 2017 validated MSIDS
questionnaire fielded by Horowitz (Citera et al., 2017). The data set comprised data from
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235 participants who met study criteria (i.e., males and females of 18 years of age or
older who had a confirmed diagnosis of Lyme disease). Of the 235 participants, 195
(83%) were females and 40 (17%) were males. The research sample, derived from the
chronic Lyme disease population, is comparable to samples of other ongoing research in
the chronic-Lyme-disease population in age and sex.
Using the three research questions, I examined sex differences in type, number,
and severity of chronic-Lyme-disease symptoms, respectively. Results from analyses
(i.e., independent samples t test, Mann–Whitney U test, and negative binomial
regression) conducted to address the research questions were not significant. Research
performed in search of differences between males and females focusing on chronic Lyme
disease has been developed using statistical observations and public CDC statistics,
highlighting the important difference between clinical practice data collection (as was
used for this study) and statistical data collection and CDC-reported cases, which are both
inherently skewed toward diagnosis, based on laboratory tests (Lee-Lewandrowski, Chen,
Branda, Baron, & Kaufman, 2019).
Relationship Between Sex of Individual and Symptoms of Lyme Disease (RQ1)
The first research question asked about the relationship between biological sex
and the frequency of symptoms in individuals with confirmed Lyme disease. The
frequencies and percentages for the 38 symptoms by sex were comparable. Indeed, the
five most prevalent Lyme-disease symptoms—fatigue, disturbed sleep, stiff neck or back,
neck cracks, and joint pain—ranked the same for males and females, varying little in
percentages. Fatigue was experienced by 90% of males and 93% of females; disturbed
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sleep was experienced by 82% of males and 88% of females; stiff neck or back was
experienced by 80% of males and 86% of females; neck cracks were experienced by 80%
of males and 81% of females; and joint pain was experienced by 77% of males and 80%
of females, reported for the individual participants in this study. Furthermore, findings
indicated that sex has no effect on the number or severity of symptoms, after controlling
for age.
Relationship with Number of Symptoms of Lyme Disease and Sex of Individual
(RQ2)
The second research inquiry was to determine what, if any, differences emerged
in the number of symptoms associated with Lyme disease between sexes of participants
with confirmed Lyme disease. This is the first study to assess sex differences in type,
number, and severity of Lyme-disease symptoms, thereby nullifying the ability to
compare results with prior work. The minimal research on chronic-Lyme-disease sex
differences has used public CDC laboratory test data rather than clinical data. For
example, Wormser and Shapiro (2009), using CDC data, found that individuals with
chronic Lyme disease were considerably more likely to be female than male, with
prevalence ratios ranging from 7:1 to 9:1. These findings differ from CDC data reports
showing higher prevalence rates of Lyme disease in males than females. Scholars have
voiced concerns about the use of laboratory data.
Females may be at higher risk of contracting chronic Lyme due to diagnostic delays if
laboratory diagnostic testing is more effective in males, as has been suggested. The
empirical focus on the diagnosis of chronic Lyme disease using CDC lab data obfuscates
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the importance of understanding potential sex differences regarding chronic Lyme
disease symptoms regardless of sex differences in prevalence rates. (Johnson, Shapiro, &
Mankoff, 2018, p. 143).
Study findings can be examined in relation to what is known in the scientific
community. In this study, the most common symptoms reported by participants—male
and female—were fatigue, disturbed sleep, stiff neck or back, neck cracks, and joint pain.
Results from the study by Rebman et al. (2017) showed that patients with chronic Lyme
disease reported significantly higher levels of fatigue, sleep problems, and pain,
compared to healthy control patients. In a study examining the effects of dapsone as a
treatment for chronic Lyme disease, Horowitz and Freeman (2016) found that chronicLyme-disease-positive/Babesia-negative patients did not evince reductions in the
symptoms of disturbed sleep and head pain posttreatment. Results from this study in
relation to those found in the Rebman et al. (2017) and Horowitz and Freeman’s (2016)
studies suggest that fatigue, disturbed sleep, and pain may be common among chronicLyme-disease patients and may be more severe in these patients than in healthy
individuals.
Relationship with Severity of Symptoms of Lyme Disease and Sex of the Individual
(RQ3)
The third research inquiry was to determine if any significant differences emerged
in the severity of symptoms associated with chronic Lyme disease and sex. It has been 4
decades since the acknowledgment of chronic Lyme disease, and still much remains
unknown regarding sex-based differences in the clinical presentation of this infection
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(Rebman et al, 2015; 2017). Indeed, sex differences in Lyme disease have not been
comprehensively examined in the literature. The only study that has examined sex
differences focused on childhood Lyme disease (Tveitnes & Oymar, 2015). The results
from Tveitnes and Oymar’s (2015) study showed that a significantly higher percentage of
girls (86%) than boys (62%) reported facial nerve palsy whereas a significantly higher
percentage of boys (30%) than girls (10%) reported headache or stiffness in the neck.
Tveitnes and Oymar’s results cannot, however, be compared to findings in this study,
conducted with adults diagnosed with chronic Lyme disease, due to the two different
types of Lyme disease, as well as age differences in hormonal production, associated
comorbidities, and duration of illness. However, Tveitnes and Oymar did emphasize the
importance of studying sex differences with regard to chronic Lyme disease and related
infections.
Limitations of the Study
As with any empirical work, this study had some limitations. The use of a
secondary data set and sex as an independent variable (that could not be manipulated)
precluded the ability to use a true experimental design and instead required the use of a
cross-sectional comparative design. The true experimental design, which has
experimental and control conditions and involves the manipulation of the independent
variable, is the only design that can determine cause and effect (Imai, Tingley, &
Yamamoto, 2013). As this study did not use a true experimental design, causality could
not be determined (i.e., that sex caused or did not cause the number or severity or
chronic-Lyme-disease symptoms).
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The original study recruitment and data-collection procedures may have
introduced certain biases, and thus limitations, into this study. The secondary data set
used for this research came from a subsample of individuals with confirmed Lyme
disease who were recruited by three practices involved in the original study. The data
accrued with recruitment through social media and the survey was provided by e-mail
invitation, directing potential participants to click on a link explaining the purpose of the
survey and informed-consent information (Citera et al., 2017). The open recruitment may
have resulted in a self-selection bias. That is, patients who had a higher number of
chronic-Lyme-disease symptoms and a higher degree of severity of symptoms may have
been more inclined to participate in the study in comparison to patients whose symptoms
were minimal or mild.
A related bias that potentially influenced study findings was the Neyman bias, or
prevalence-incidence bias, which happens as a result of a significant amount of time
passing between exposure to a disease and the investigation and reporting of the disease
and its symptoms (Tripepi, Jager, Dekker, & Zoccali, 2010). The Neyman bias is a
problem in cross-sectional research (Yu & Tse, 2002). The data set contained information
from prevalence cases, which are typically more ill patients, rather than incidence cases,
or newly diagnosed patients. Thus, the original open-recruitment process may have
excluded patients with few disease symptoms and low severity of symptoms but included
patients with a high number or more severe symptoms. The symptoms reported by
participants may have been influenced by the length of time since infection/reinfection
and diagnosis: participants who were infected for a longer period of time or reinfected
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may have more symptoms or more severe symptoms. Moreover, the time of infection and
time of diagnosis were potential confounding variables that could not be addressed in this
study.
Additional limitations included that the data set did not include information on
comorbidities associated with chronic Lyme disease that may have exacerbated
symptoms. Individuals can have a number of symptoms that fall under the broad
spectrum of more than one disease, due to a multisystem immunological breakdown over
years of multiple health issues (Crystal, 2019). Another concern was that the existing
ELISA serologic test for Lyme disease may have resulted in the initial exclusion of
patients who actually did have Lyme disease. A positive ELISA test result only proves
exposure to the Borrelia infection and does not indicate a current infection. Thus, the test
can indicate a historical or late-stage (chronic-Lyme-disease) infection. In contrast, false
negative results are typical, especially if the seroconversion postinfection has not
occurred. Seroconversion can take up to 8 weeks before true positivity is proven
(AMBOSS, 2020).
Recommendations
This study can prompt the development of future empirical work. The outcomes
from this research show no statistically significant differences between males and
females with respect to the type, frequency and severity of symptoms for chronic Lyme
disease. It is important to note, however, that this is the only study to date that has
examined potential sex differences regarding the type, number, and severity of chronic
Lyme disease symptoms. There remains a need for additional studies. The analysis of this
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research highlighted the unintentional imbalance in study participants with more females
than males. Replication studies, especially those utilizing sex-equivalent sample groups,
are needed to affirm or contradict the non-significant findings noted in this study. Crosssectional studies that control for or include as additional independent variables pertinent
factors such as ethnicity, geographical residence, time since infection or diagnosis, and
additional diagnoses are needed, as they may parse out significant effects and/or
interactions that could not be assessed in this study. Studies utilizing different
observational designs, such as cohort studies (i.e., comprised of a sample of exposed and
non-exposed patients) and case control studies (i.e., comprised of a sample of patients
with and without Lyme disease) would be beneficial. Indeed, the case-control approach
has become the primary design used in chronic disease epidemiological research
(Giesecke, 2017).
Knowing the age of the individual is important for assessment of the individual’s
status of immunity. Future research should consider that an individual’s immune system
changes with aging and then the immune system becomes slower to respond; the body
may heal more slowly; changes in hormone production; the immune system’s ability to
detect and correct cell defects declines; and autoimmune disorders may develop which all
effects of aging (Martin, Zieve, & Conaway, 2018). There is a strong argument for
considering age-related per sex clinical assessments and diagnostic testing requirements
in future research to eliminate overlooking Lyme disease infections.
The study findings were dependent upon the appropriate diagnosis of Lyme
disease and chronic Lyme disease. There remains, however, uncertainty among
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physicians regarding the cause, origin, and specific diagnostic criteria of chronic Lyme
disease (Greenberg, 2017). Clinical assessment by non-Lyme-literate practitioners can
lead to misdiagnoses and affect proper reporting of chronic Lyme disease symptoms with
related frequency of those symptoms. There is a need for continuous dialogue among
practitioners regarding diagnostic and treatment concerns for chronic Lyme disease. The
difficulty that physicians have diagnosing chronic Lyme disease is due in part to the lack
of use of a standardized assessment tool, such as the MSIDS (Horowitz, 2013). Not only
is there a need for additional studies that use the MSIDS, there is a need to train
practitioners on the use of this and other assessments. Moreover, as treatment response
may differ between males and females, there is a need for practical assessment and
empirical examination of potential sex differences with regard to treatment modalities.
Implications
This secondary data set does not identify pertinent research differences in chronic
Lyme disease between females and males. These findings were unremarkable between
sexes seen in this research. However, current research in 2018, performed in both rural
and urban areas, shows more medical claim lines with Lyme disease diagnoses were
submitted for females than males (FAIR Health, 2019; Leland, 2019). Additionally,
Lyme disease diagnoses by sex in rural areas (56% females & 44% males) was slightly
less than in urban areas (61% females & 39% males) (FAIR Health, 2019). The question
regarding the knowledge of the practitioner performing the clinical assessment and
whether or not the practitioner understands that the symptoms can reflect late stage or
chronic Lyme disease. According to Rebman et al. (2015), comparison to other infectious
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and chronic diseases where sex differences are more pronounced, differences in the
number of CDC-reported cases of Lyme disease by sex are unremarkable. That question
that one then asks is “Why?”
A better data set for researching the differences in the symptoms and severity of
symptoms with chronic Lyme disease should begin with a managed recruitment with
equal cohorts for analysis to ensure a potentially more appropriate outcome. As
previously stated, annually CDC-reported number of confirmed cases of Lyme disease in
the U.S. from 2001 to 2017, are listed by age and sex, and the outcome just from that
report identifies more cases reported for males (214,885) compared to females (168,961)
across all age groups (Elflein, 2019). With any other indication, age is a condition
considered when diagnosis is being determined and the age of individual specific to their
sex identifier, is medical common sense for consideration. Unfortunately, a large portion
of the medical community does not believe that chronic Lyme disease is a problem, nor
indeed, that it exists (Cox, 2019).
It is important that practitioners understand the risks associated with chronic
Lyme disease. A misdiagnosis of chronic Lyme disease can lead to further misdiagnoses,
especially among sexes. For example, individuals with chronic Lyme disease may not
realize the associated cancer risk they have (Envita Medical Center, 2019). The Envita
Medical Center (2019) reported having a surprisingly high number of patients with latestage cancer who tested positive for Lyme disease. The organization also reported an
association between Lyme disease and tumor development (in both males and females)
(Envita Medical Center, 2019). The need for diagnosing Lyme disease, whether acute or
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chronic, in males or females, is critical in not only proper diagnosis of Lyme disease but
to further prevent the development of associated chronic or terminal diseases.
Conclusion
Lyme disease is known as the great imitator as its symptoms mimic or imitate up
to 350 different diseases (Mott, 2019). Lyme disease is quickly becoming the untreated
epidemic of the 21st century, as patients around the world struggle to find a “Lymeliterate” doctor who can help them regain their health, often without success (Holtorf,
2020). Many physicians have only a general textbook understanding of Lyme disease and
its symptomatology, and if they do have a deeper understanding of the disease, they often
do not understand the complexity in the presentations of Lyme disease symptoms
(IGeneX, 2020). Moreover, the symptoms of Lyme disease may differ and/or be more or
less pronounced among individuals, depending on susceptibility criteria such as sex
(Columbia University Irvine Medical Center, 2018).
Many individuals with Lyme disease often continue to experience
symptomatology after treatment and may be diagnosed as having chronic Lyme disease.
Multiple symptoms can present at various times for an individual with chronic Lyme
disease, which can be migratory, resulting in an ebb and flow in the number and severity
of symptoms. Chronic Lyme disease remains a controversial diagnosis, with some
physicians disagreeing as to its actual existence (Horowitz, 2013). Moreover, the nonspecific symptoms associated with chronic Lyme disease makes clinical assessments
difficult to diagnose and treat properly (Holtorf, 2020). Controversies surrounding its
actual existence coupled with the lack of valid and reliable diagnostic assessments for
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chronic Lyme disease likely contributed to the lack of empirical examination of potential
sex differences with regard to the type, number, and severity of symptoms. This is a
concern, as sex analysis is a critical element of health systems research (London School
of Hygiene & Tropical Medicine, 2014).
The findings from this study indicated no sex differences with regard to type,
number, and severity of chronic Lyme disease symptoms. This, however, was just one
study, and certain study limitations and biases (discussed previously) may have
contributed to the non-significance of findings. There remains a crucial need for
additional studies that examine sex differences with regard to symptoms for both Lyme
disease and chronic Lyme disease. Understanding sex-based differences, such as sexbased antibodies to diseases, is becoming more obviously important as the issue of sex
bias is much deeper than clinical presentation (Lymedisease.org, 2020). Going forward, it
is imperative that individuals research and seek out referrals to Lyme-literate
practitioners before spending precious time and money on diagnostics that may be
inconclusive and treatments that may do more harm than good.
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